US20200140806A1 - Food grade bacteria for the removal of toxic compounds - Google Patents
Food grade bacteria for the removal of toxic compounds Download PDFInfo
- Publication number
- US20200140806A1 US20200140806A1 US16/676,021 US201916676021A US2020140806A1 US 20200140806 A1 US20200140806 A1 US 20200140806A1 US 201916676021 A US201916676021 A US 201916676021A US 2020140806 A1 US2020140806 A1 US 2020140806A1
- Authority
- US
- United States
- Prior art keywords
- lactobacillus
- food
- bacteria
- grade bacteria
- grade
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 231100000167 toxic agent Toxicity 0.000 title claims abstract description 82
- 241000894006 Bacteria Species 0.000 title abstract description 182
- 235000013305 food Nutrition 0.000 title description 69
- 238000000034 method Methods 0.000 claims abstract description 59
- 229910052793 cadmium Inorganic materials 0.000 claims abstract description 35
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 claims abstract description 31
- 239000000126 substance Substances 0.000 claims abstract description 30
- 229910052785 arsenic Inorganic materials 0.000 claims abstract description 26
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 claims abstract description 25
- 241000186660 Lactobacillus Species 0.000 claims description 91
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 52
- 239000003440 toxic substance Substances 0.000 claims description 52
- 229940039696 lactobacillus Drugs 0.000 claims description 45
- 239000000203 mixture Substances 0.000 claims description 43
- 244000199866 Lactobacillus casei Species 0.000 claims description 29
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 28
- 229940017800 lactobacillus casei Drugs 0.000 claims description 28
- 239000005949 Malathion Substances 0.000 claims description 25
- JXSJBGJIGXNWCI-UHFFFAOYSA-N diethyl 2-[(dimethoxyphosphorothioyl)thio]succinate Chemical compound CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC JXSJBGJIGXNWCI-UHFFFAOYSA-N 0.000 claims description 25
- 229960000453 malathion Drugs 0.000 claims description 25
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 claims description 25
- 239000000284 extract Substances 0.000 claims description 18
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 16
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 15
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 15
- 241001468157 Lactobacillus johnsonii Species 0.000 claims description 9
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 8
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 8
- 241000186713 Lactobacillus amylovorus Species 0.000 claims description 6
- 241000218492 Lactobacillus crispatus Species 0.000 claims description 6
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 6
- 229940012969 lactobacillus fermentum Drugs 0.000 claims description 6
- 230000014759 maintenance of location Effects 0.000 claims description 6
- 235000013336 milk Nutrition 0.000 claims description 6
- 239000008267 milk Substances 0.000 claims description 6
- 210000004080 milk Anatomy 0.000 claims description 6
- 230000002496 gastric effect Effects 0.000 claims 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 abstract description 54
- 229910052753 mercury Inorganic materials 0.000 abstract description 53
- 239000000575 pesticide Substances 0.000 abstract description 22
- 210000004027 cell Anatomy 0.000 description 76
- 239000000243 solution Substances 0.000 description 53
- 229910052751 metal Inorganic materials 0.000 description 28
- 239000002184 metal Substances 0.000 description 28
- 239000002054 inoculum Substances 0.000 description 25
- 238000001878 scanning electron micrograph Methods 0.000 description 25
- 229910001385 heavy metal Inorganic materials 0.000 description 18
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 17
- 239000007995 HEPES buffer Substances 0.000 description 17
- 230000001580 bacterial effect Effects 0.000 description 16
- 238000011534 incubation Methods 0.000 description 16
- 241000588724 Escherichia coli Species 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 15
- 239000006041 probiotic Substances 0.000 description 15
- 235000018291 probiotics Nutrition 0.000 description 15
- 241000282414 Homo sapiens Species 0.000 description 14
- 241000894007 species Species 0.000 description 14
- 150000002739 metals Chemical class 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 238000005119 centrifugation Methods 0.000 description 10
- 210000001035 gastrointestinal tract Anatomy 0.000 description 10
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 230000000529 probiotic effect Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 239000003053 toxin Substances 0.000 description 8
- 231100000765 toxin Toxicity 0.000 description 8
- 108700012359 toxins Proteins 0.000 description 8
- 238000001784 detoxification Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 238000011870 unpaired t-test Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 230000035899 viability Effects 0.000 description 6
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 5
- 238000009631 Broth culture Methods 0.000 description 5
- AQLMHYSWFMLWBS-UHFFFAOYSA-N arsenite(1-) Chemical compound O[As](O)[O-] AQLMHYSWFMLWBS-UHFFFAOYSA-N 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 238000002149 energy-dispersive X-ray emission spectroscopy Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 230000009919 sequestration Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 229930195730 Aflatoxin Natural products 0.000 description 4
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 4
- 241000186000 Bifidobacterium Species 0.000 description 4
- 241000193163 Clostridioides difficile Species 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 239000005409 aflatoxin Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000002482 cold vapour atomic absorption spectrometry Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 229910052745 lead Inorganic materials 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 235000020183 skimmed milk Nutrition 0.000 description 4
- ZNJHFNUEQDVFCJ-UHFFFAOYSA-M sodium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[Na+].OCCN1CCN(CCS(O)(=O)=O)CC1 ZNJHFNUEQDVFCJ-UHFFFAOYSA-M 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 3
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 241000508269 Psidium Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 150000001720 carbohydrates Chemical group 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229910052762 osmium Inorganic materials 0.000 description 3
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- -1 troches Substances 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- DJHGAFSJWGLOIV-UHFFFAOYSA-K Arsenate3- Chemical compound [O-][As]([O-])([O-])=O DJHGAFSJWGLOIV-UHFFFAOYSA-K 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- 231100000678 Mycotoxin Toxicity 0.000 description 2
- ZRWPUFFVAOMMNM-UHFFFAOYSA-N Patulin Chemical compound OC1OCC=C2OC(=O)C=C12 ZRWPUFFVAOMMNM-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002115 aflatoxin B1 Substances 0.000 description 2
- OQIQSTLJSLGHID-WNWIJWBNSA-N aflatoxin B1 Chemical compound C=1([C@@H]2C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O OQIQSTLJSLGHID-WNWIJWBNSA-N 0.000 description 2
- 229930020125 aflatoxin-B1 Natural products 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229940000489 arsenate Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 238000000724 energy-dispersive X-ray spectrum Methods 0.000 description 2
- 231100000317 environmental toxin Toxicity 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229960005051 fluostigmine Drugs 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000002923 metal particle Substances 0.000 description 2
- 239000002636 mycotoxin Substances 0.000 description 2
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 230000005195 poor health Effects 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241001134770 Bifidobacterium animalis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 244000133098 Echinacea angustifolia Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001646719 Escherichia coli O157:H7 Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 241000254697 Lactobacillus rhamnosus HN001 Species 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- JJWSNOOGIUMOEE-UHFFFAOYSA-N Monomethylmercury Chemical compound [Hg]C JJWSNOOGIUMOEE-UHFFFAOYSA-N 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- VYLQGYLYRQKMFU-UHFFFAOYSA-N Ochratoxin A Natural products CC1Cc2c(Cl)cc(CNC(Cc3ccccc3)C(=O)O)cc2C(=O)O1 VYLQGYLYRQKMFU-UHFFFAOYSA-N 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 101710126321 Pancreatic trypsin inhibitor Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 108010079723 Shiga Toxin Proteins 0.000 description 1
- 239000000589 Siderophore Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- LULLIKNODDLMDQ-UHFFFAOYSA-N arsenic(3+) Chemical compound [As+3] LULLIKNODDLMDQ-UHFFFAOYSA-N 0.000 description 1
- 210000004082 barrier epithelial cell Anatomy 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 235000020237 cranberry extract Nutrition 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000014134 echinacea Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000012020 french fries Nutrition 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003673 groundwater Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 241000238565 lobster Species 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000002731 mercury compounds Chemical class 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 231100000783 metal toxicity Toxicity 0.000 description 1
- 229910052752 metalloid Inorganic materials 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229910052755 nonmetal Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- RWQKHEORZBHNRI-BMIGLBTASA-N ochratoxin A Chemical compound C([C@H](NC(=O)C1=CC(Cl)=C2C[C@H](OC(=O)C2=C1O)C)C(O)=O)C1=CC=CC=C1 RWQKHEORZBHNRI-BMIGLBTASA-N 0.000 description 1
- DAEYIVCTQUFNTM-UHFFFAOYSA-N ochratoxin B Natural products OC1=C2C(=O)OC(C)CC2=CC=C1C(=O)NC(C(O)=O)CC1=CC=CC=C1 DAEYIVCTQUFNTM-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000000424 optical density measurement Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000013310 pig model Methods 0.000 description 1
- 235000021135 plant-based food Nutrition 0.000 description 1
- 235000013606 potato chips Nutrition 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000005067 remediation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 230000012780 sequestering of mercury Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 235000019722 synbiotics Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 229940108519 trasylol Drugs 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000002349 well water Substances 0.000 description 1
- 235000020681 well water Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A62—LIFE-SAVING; FIRE-FIGHTING
- A62D—CHEMICAL MEANS FOR EXTINGUISHING FIRES OR FOR COMBATING OR PROTECTING AGAINST HARMFUL CHEMICAL AGENTS; CHEMICAL MATERIALS FOR USE IN BREATHING APPARATUS
- A62D3/00—Processes for making harmful chemical substances harmless or less harmful, by effecting a chemical change in the substances
- A62D3/02—Processes for making harmful chemical substances harmless or less harmful, by effecting a chemical change in the substances by biological methods, i.e. processes using enzymes or microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
-
- C12R1/225—
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Definitions
- the present invention relates to food grade bacteria for improving detoxification. More particularly, the present invention relates to food grade bacteria, or extracts thereof, and to methods of using food grade bacteria or extracts thereof to reduce uptake of ingested toxic compounds and to methods of sequestering toxic compounds from the environment to which the food-grade bacteria is exposed to.
- probiotics are one of the fastest growing food segments in North America.
- gaining insight into the mechanisms by which indigenous microbes and exogenous probiotics affect the subject has been limited.
- Probiotic Lactobacilli and bifidobacteria have been shown to help manage several gut pathologies.
- U.S. Pat. No. 6,641,808 disclosing the use of Lactobacilli for the treatment of obesity
- U.S. Pat. No. 5,531,988 discloses a mixture of an immunoglobulin and a bacterium, such as Lactobacilli or bifidobacterium or mixtures thereof, that may be used to treat diarrhea, constipation, and gas/cramps
- U.S. Pat. No. 6,080,401 discloses a combination of probiotics having Lactobacillus acidophilus and Bifidobacterium bifidus and herbal preparations for aiding in weight loss, and so forth.
- Lactobacilli and/or bifidobacteria have been found to alter the subject's intestinal metabolic signature [Ndagijimana, M. Laghi L, Vitali B, Placucci G, Brigidi P, Guerzoni M E. Effect of synbiotic food consumption on human gut metabolic profiles evaluated by 1H nuclear magnetic resonance spectroscopy. Int J Food Microbiol. 2009; 134: 147-153]; bind to aflatoxin ( Lactobacillus strains) [Hernandez-Mendoza A, Garcia H S, Steele J L. Screening of Lactobacillus casei strains for their ability to bind aflatoxin B1.
- Heavy metal toxicity is one of the largest health risks in the 21st century. Consumption of lead and cadmium through environmental exposure and diet has been directly responsible for poor health outcomes including: impaired neurological function and loss of IQ, osteoporosis, lung and kidney cancer.
- Heavy metals such as lead and cadmium are present in the natural environment, and therefore many bacteria over time have developed mechanisms of resistance to these metals which generally include actively precipitating and sequestering the metals intra/extra cellular or the active efflux of metals out of the cell cytoplasm.
- Non-food grade bacteria have been investigated for their use in sequestration and detoxification of heavy metals and have shown success (JS Singh et al. Genetically engineered bacteria: An emerging tool for environmental remediation and future research perspectives. Gene. July 2011. 40 (1-2):1-9); Rajkumar et al. Potential of siderophore-producing bacteria for improving heavy metal phytoextraction. Trends Biotechnol. March 2010. 28 (3):142-149).
- Mercury is one of the most toxic substances known to man and its consumption by a subject is linked to poor health outcomes including altered neurological development in children. Yet, North Americans and Europeans are estimated to consume 6.7 ⁇ g daily of inorganic mercury and methylmercury (World Health Organization, 1991).
- Arsenic is a metalloid element which commonly comes in two oxidation states: arsenate (As V) and arsenite (As III). Arsenic is found distributed globally often in the earth's crust, it is highly soluble in water and is found in high concentrations in ground water. Arsenic toxicity has been linked to a number of cases and is known to cause organ failure, cancer and death. Main routes of exposure is through ingestion via diet, often arsenic contaminated waters are used for irrigation of farmland resulting in accumulation of the metal in plants and food.
- Pesticides such as malathion and parathion fall into the class of organophosphate compounds and act as cholinesterase inhibitors.
- Malathion is one of the most widely used pesticides in the U.S., and parathion use has recently been limited and is not used in many developed countries due to high toxicity.
- produce imports still consistently detect levels of parathion on produce and it is used in some rare instances in North America.
- the present invention provides methods and uses of food grade bacteria for removal and/or neutralization of toxic products found in the internal environment of animals, in the environment to which the animal is exposed or in substance ingested or to be ingested by the animals that may avoid adverse side effects, is reasonable in cost, and may be beneficial in reducing the risk of diseases related to said toxic products. Further, the present invention is relatively easy to manufacture and deliver to a subject.
- the present invention provides food-grade bacteria or extracts thereof for removing of toxic compounds from a substance or environment to which the food-grade bacteria is exposed to.
- the present invention provides for a composition comprising a food-grade bacteria and a suitable carrier, whereby the composition comprises an effective dose of the food-grade bacteria to remove a toxic compound from a substance or environment to which the food-grade bacteria is exposed to.
- the therapeutically effective dose is at least about 1 ⁇ 10 9 of the food-grade bacteria per milliliter or less of the suitable carrier.
- the suitable carrier is a carbohydrate-containing medium.
- the carbohydrate-containing medium is a milk-based product.
- the toxic compound is selected from the group consisting of lead, cadmium, mercury, arsenic, malathion and parathion.
- the food-grade bacteria are provided dead or live.
- the food-grade bacteria are provided as an extract.
- the composition comprises a combination of two or more different species of food-grade bacteria.
- the composition comprises a combination of two or more strains of Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus crispatus, Lactobacillus fermentum, Lactobacillus johnsonii, Lactobacillus plantarum, Lactobacillus reuteri , and Lactobacillus amylovorus.
- the food-grade bacteria is selected from the group of food-grade bacteria listed in Table 1 shown bellow. It is mentioned that a bacteria strain of interest is the Lactobacillus rhamnosus strain deposited, according to the Budapest Treaty, at CNCM (Collection Nationale de Cultures de Microorganismes, 25 rue du Dondel Roux, Paris) on Mar. 5, 2013, under the accession number CNCM 1-4719. This strain is also referred to as “DN 116-060” or R37.
- the environment is an aqueous environment.
- the present invention is a composition, the composition including food-grade bacteria, a carrier and an animal's feed, wherein the food-grade bacteria is capable of removing a toxic compound from a substance or environment to which the food-grade bacteria is exposed to and the food-grade bacteria comprises a bacterial isolate selected from the group consisting of the food-grade bacteria listed in Table 1 or any combination thereof.
- the present invention is a method for reducing a subject uptake of toxic compounds consumed by the subject, the method including administering to the subject an effective dose of a food-grade bacteria capable of sequestering the toxic compound consumed by the subject.
- a method for removing a toxic compound from a substance or environment which is contaminated or suspected of being contaminated with the toxic compound including contacting the substance or environment with food-grade bacteria capable of removing the toxic compound from the substance or the environment.
- the present invention is a method of reducing the toxic effects of a toxic compound in a subject, the method including: administering to the subject a therapeutically effective amount of a food-grade bacteria capable of removing the toxic compound from a substance or environment.
- the toxic compound is selected from the group consisting of lead, cadmium, mercury, arsenic, malathion and parathion.
- the food-grade bacteria are provided dead or live.
- the food-grade bacteria are provided as an extract.
- the food-grade bacteria comprise a combination of two or more different species of food-grade bacteria.
- the composition comprises a combination of two or more strains of Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus crispatus, Lactobacillus fermentum, Lactobacillus johnsonii, Lactobacillus plantarum, Lactobacillus reuteri , and Lactobacillus amylovorus
- the food grade bacteria are selected from the group of food-grade bacteria listed in Table 1.
- the present invention is a method of obtaining a strain of Lactobacillus capable of removing a toxic compound from an environment, the method including a step of mutagenesis or genetic transformation of the Lactobacilus.
- the present invention is a method for obtaining a cell fraction capable of removing a toxic compound from an environment, including the steps of: a) culturing a Lactobacillus strain, and b) recovering the cell fraction from the culture in step a).
- the toxic compound is selected from the group consisting of lead, cadmium, mercury, arsenic, malathion and parathion.
- Lactobacillus is provided dead or live.
- the Lactobacillus is provided as an extract.
- the Lactobacillus includes a combination of two or more different strains.
- the Lactobacillus is selected from the group of Lactobacilli listed in Table 1.
- the present invention is a use of a food grade bacteria for the removal of a toxic compound from a substance or an environment.
- the toxic compound is selected from the group consisting of lead, cadmium, mercury, arsenic, malathion and parathion.
- the food-grade bacteria are provided dead or live.
- the food-grade bacteria are provided as an extract.
- the food grade bacteria are provided as a combination of two or more different species of food-grade bacteria.
- the food grade bacteria are provided as two or more strains of Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus crispatus, Lactobacillus fermentum, Lactobacillus johnsonii, Lactobacillus plantarum, Lactobacillus reuteri , and Lactobacillus amylovorus.
- the food-grade bacteria is selected from the group of food-grade bacteria listed in Table 1.
- the present invention provides for a method for removing a toxic compound from a substance which is suspected of being contaminated with said toxic compound comprising contacting the substance with food-grade bacteria or extract thereof capable of removing the toxic compound from the substance.
- the present invention provides for a method of reducing the toxic effects of a toxic compound in a subject, the method comprising: administering to the subject a therapeutically effective amount of food-grade bacteria of Table 1 or any combination thereof.
- the present invention provides for a method of obtaining a strain of Lactobacillus capable of removing a toxic compound from an environment, the method includes a step of mutagenesis or genetic transformation of the Lactobacilus.
- the present invention is a method for obtaining a cell fraction capable of removing a toxic compound from an environment.
- the method includes the steps of: a) culturing a Lactobacillus strain, and b) recovering the cell fraction from the culture in step a).
- the food-grade bacteria comprise a combination of two or more different species of food-grade bacteria.
- the food grade bacteria is a Lactobacillus.
- the toxic compound includes a heavy metal.
- the toxic compound includes a heavy metal and the food-grade bacteria comprise dead bacteria.
- the toxic compound includes a heavy metal and the food-grade bacteria comprise live bacteria.
- the toxic compound includes a heavy metal and the food-grade bacteria comprise a mixture of dead bacteria and live bacteria.
- the heavy metal is cadmium.
- the heavy metal is lead.
- the toxic compound includes mercury.
- the mercury is inorganic mercury.
- the mercury is organic mercury.
- the toxic compound includes mercury and the food-grade bacteria comprise dead bacteria.
- the toxic compound includes mercury and the food-grade bacteria comprise live bacteria.
- the toxic compound includes mercury and the food-grade bacteria comprise a mixture of dead bacteria and live bacteria.
- the toxic compound includes arsenic.
- the toxic compound includes arsenic and the food-grade bacteria comprise dead bacteria.
- the toxic compound includes arsenic and the food-grade bacteria comprise live bacteria.
- the toxic compound includes arsenic and the food-grade bacteria comprise a mixture of dead bacteria and live bacteria.
- the toxic compound includes a pesticide.
- the toxic compound includes a pesticide and the food-grade bacteria comprise dead bacteria.
- the toxic compound includes a pesticide and the food-grade bacteria comprise live bacteria.
- the toxic compound includes a pesticide and the food-grade bacteria comprise a mixture of dead bacteria and live bacteria.
- the pesticide is selected from malathion or parathion.
- the toxic compound includes endotoxins.
- the toxic compound includes heterocyclic aromatic amines.
- the toxic compound includes acrylamide.
- FIG. 1A is a graph illustrating the ability of food grade Lactobacilli to remove lead (Pb) from a solution (error bars ⁇ SEM).
- FIG. 1B is a graph illustrating the ability of food grade Lactobacilli to remove cadmium (Cd) from a solution (error bars ⁇ SEM).
- FIG. 2A is a graph illustrating the ability of food grade Lactobacilli to remove lead (Pb) from a solution compared to E. coli (error bars ⁇ SEM).
- FIG. 2B is a graph illustrating the ability of food grade Lactobacilli to remove cadmium (Cd) compared to E. coli (error bars ⁇ SEM).
- FIG. 3A is a graph illustrating the ability of live and dead food grade Lactobacilli to remove lead (Pb) from a solution (error bars ⁇ SEM).
- FIG. 3B is a graph illustrating the ability of live and dead food grade Lactobacilli to remove cadmium (Cd) from a solution (error bars ⁇ SEM).
- FIGS. 4A-4C are TEM microphotographs of Lactobacillus rhamnosus R37 incubated with a control buffer without the addition of metals ( FIG. 4A ), lead ( FIG. 4B ), and mercury ( FIG. 4C ).
- FIGS. 5A-5C are scanning electron micrographs of Lactobacillus rhamnosus R37 incubated with a control buffer without the addition of metals ( FIG. 5A ), lead ( FIG. 5B ), and mercury ( FIG. 5C ).
- FIG. 6A is a scanning electron micrograph of Lactobacillus rhamnosus R37 (top) and a corresponding energy-dispersive X-ray spectrum of a portion of a cell not containing visible deposits.
- FIG. 6B is a scanning electron micrograph of Lactobacillus rhamnosus R37 (top) and a corresponding energy-dispersive X-ray spectrum of a portion of a cell containing visible deposits.
- FIGS. 7A-7C are scanning electron microphotographs of Lactobacillus rhamnosus GR-1 incubated with lead ( FIG. 7A ), cadmium ( FIG. 7B ), and a control without the addition of metals ( FIG. 7C ).
- FIGS. 8A-8D are flow cytometry analysis of Caco-2 cell line comparing viability vs. mortality of untreated cells ( FIG. 8A ), cells exposed to cadmium ( FIG. 8B ), cells exposed to Lactobacillus plantarum 14917T ( FIG. 8C ), and cells exposed to Lactobacillus plantarum 14917T and then exposed to cadmium ( FIG. 8D ).
- FIG. 9A is a graph illustrating the growth of a number of Lactobacilli species in Man Rogosa Sharpe (MRS) media having lead.
- FIG. 9B is a graph illustrating the growth of a number of Lactobacilli species in MRS media having cadmium.
- FIG. 10A is a graph illustrating the ability of a food grade bacterium of the present invention to remove Hg 2+ from a solution having a 1 part per million (ppm) Hg 2+ inoculum (error bars ⁇ SEM; * signifies significant (p ⁇ 0.05) difference by an unpaired T-test).
- FIG. 10B is a graph illustrating the ability of a food grade bacterium of the present invention to remove Hg 2+ from a solution having a 15 part per billion (ppb) Hg 2+ inoculum (error bars ⁇ SEM; * signifies significant (p ⁇ 0.05) difference by an unpaired T-test).
- FIG. 11 is a graph illustrating the ability of a food grade bacterium of the present invention to remove organic mercury from a solution (error bars ⁇ SEM; * signifies significant (p ⁇ 0.05) difference by an unpaired T-test).
- FIG. 12 is a graph illustrating the ability of live and dead food grade bacterium of the present invention to remove inorganic mercury from a solution (error bars ⁇ SEM; * signifies significant (p ⁇ 0.05) difference by an unpaired T-test).
- FIGS. 13A-13B are graphs illustrating variability of mercury resistance within a group of food grade bacteria of the genus Lactobacillus .
- FIG. 13A illustrates growth of different strains of Lactobacillus casei in a gradient of Hg 2+ and
- FIG. 13B illustrates growth of different strains of Lactobacillus rhamnosus in a gradient of Hg 2+ .
- FIG. 14 is a graph illustrating twenty-four hour time course of mercury removal by Lactobacillus rhamnosus R37 and GR-1 in HEPES-NaOH supplemented with 1 ⁇ g/mL HgCl 2 incubated at 37° C.
- FIGS. 15A-15B are graphs illustrating removal of mercury from solution by a selection of Lactobacillus rhamnosus strains of increased resistance (R) and strains of increased sensitivity (S) to mercury at HgCl 2 concentrations of 0.5 ppm ( FIG. 15A ) and 1 ppb ( FIG. 15B ).
- FIG. 16 is a graph illustrating the ability of food grade bacteria and E. coli species to remove As (III) and As (V) from solution at starting inoculums of 10 ppm.
- FIG. 17 is a graph illustrating the ability of food grade bacteria to remove As (III) from solution at a starting inoculums of 1 ppm. (Error bars ⁇ SEM).
- FIG. 18 is a graph illustrating the ability of Lactobacilli to remove As (III) from solution at starting inoculums of 100 ppm.
- FIGS. 19A-19B are graphs depicting the ability of probiotic bacteria to remove malathion ( FIG. 19A ) and parathion ( FIG. 19B ) from solution.
- Starting inoculums for malathion and parathion are 5 ⁇ g and 0.5 ⁇ g respectively. (Error bars ⁇ SEM).
- FIG. 20 is a graph illustrating the ability of a probiotic bacterium to remove both malathion and parathion from solution simultaneously. Malathion original concentration was 5 ⁇ g while parathion was 0.5 ⁇ g. (Error bars ⁇ SEM).
- FIGS. 21A-21B are graphs depicting the ability of food grade bacteria and E. coli to remove malathion ( FIG. 21A ) or parathion ( FIG. 21B ) from solution.
- Starting inoculums of pesticides for malathion and parathion was 10 mg/L and 3 mg/L respectively. (Error bars ⁇ SEM).
- food grade bacteria refers to any bacteria, alive or dead, that have no harmful effect on human health or that have a GRAS (generally recognized as safe) status. Such bacteria maybe selected from the group consisting of Lactobacilli and Bacilli. Non-limiting examples of food-grade bacteria particularly suitable for the purpose of the present invention are listed in Table 1.
- probiotic refers to food-grade bacteria which perform beneficial functions to subject organisms when they are present and alive in viable form in the subject organisms.
- Food production animal is used herein to describe any animal that is prepared and used for human consumption.
- a food production animal can be, but not limited to, a ruminant animal such as beef and dairy cattle, pigs, lamb, chicken, turkey or any other fowl, or aquatic animals including shrimp, lobster or fish used for human consumption.
- removing a toxic compound from a substance or environment refers to a removal of one or more toxic compounds that can be tested as described in at least one of the examples below.
- Subject or “subjects” are used herein to describe a member of the animal kingdom, including food production animals and humans.
- mutant strains or genetically transformed strains derived from a parent strain can be strains wherein one or more endogenous gene(s) of the parent strain has (have) been mutated, for instance to modify some of its metabolic properties (e.g., its ability to ferment sugars, its resistance to acidity, its survival to transport in the gastrointestinal tract, its post-acidification properties or its metabolite production). They can also be strains resulting from the genetic transformation of the parent strain by one or more gene(s) of interest, for instance in order to confer to said genetically transformed strains additional physiological features, or to allow it to express proteins of therapeutic or vaccinal interest that one wishes to administer through said strains.
- strains can be obtained from a strain by means of the conventional techniques for random or site-directed mutagenesis and genetic transformation of Lactobacilli , such as those described by Gury et al. (2004) or by Perea Vélez et al., 2007, or by means of the technique known as “genome shuffling” (Patnaik et al., 2002 and Wang et al., 2007).
- a subject of the present invention is also cell fractions which can be obtained from a Lactobacillus strain. They are in particular DNA preparations or bacterial wall preparations obtained from cultures of said strain. They may also be culture supernatants or fractions of these supernatants.
- cell-free supernatant (CFS) of one Lactobacillus strain can be obtained using the method for obtaining a CFS from another Lactobacillus strain.
- a subject of the present invention is also a method for obtaining a cell fraction, comprising the steps of:
- step a) culturing a Lactobacillus strain, and b) obtaining and/or recovering the cell fraction from the culture in step a).
- said strain can be used in the form of whole bacteria which may be living or dead.
- said strain can be used in the form of a bacterial lysate or in the form of bacterial fractions; the bacterial fractions suitable for this use can be chosen, for example, by testing their properties on mercury removal from an aqueous environment.
- the bacterial cells are present as living, viable cells.
- the present invention relates to food-grade bacterial or extracts thereof, including probiotics, capable of removing or sequestering toxic compounds from an environment to which the food-grade bacteria is exposed to, or from a substance which may have or may be suspected of having the toxic compound.
- Substances may include edible compositions, such as vegetable-based foods or animal-based foods, and may also include drinkable solutions, including water, milk, syrups, extracts and other beverages. Substances may also include raw agricultural products used to produce foods and drinkable solutions.
- the present invention relates also to methods of using the food-grade bacteria of the present invention to prevent the uptake of toxic compounds by a subject, or in methods to filter toxic compounds out of substances prior to exposing a subject to said substances.
- the environment may include an aqueous environment, such as the gastro-intestinal tract of a subject, or the environment in which the subject resides, such as a pond.
- the food grade bacteria may be any type of bacteria that may be capable of removing toxic compounds from foods or solutions that may be consumed by a subject, or from ingredients used in the manufacture of said foods or solutions.
- Table 1 includes food-grade bacteria that may be used with the present invention.
- the food-grade bacteria may be aerobically, microaerophilically or anaerobically grown and may be selected from the group consisting of the food-grade bacteria of Table 1.
- Administration of the food-grade bacteria, or extract thereof, to a subject may be accomplished by any method likely to introduce the organisms into the gastro-intestinal tract of the subject.
- the bacteria can be mixed with a carrier and applied to liquid or solid feed or to drinking water.
- the carrier material should be non-toxic to the subject.
- the carrier material should also be non-toxic to the food-grade bacteria.
- the carrier preferably, may include an ingredient that promotes viability of the bacteria during storage.
- the food-grade bacteria may also be formulated as an inoculant paste to be directly injected into a subject's mouth.
- the formulation may include added ingredients to improve palatability, improve shelf-life, impart nutritional benefits, and the like.
- the food-grade bacteria can be administered by a cannula or syringe.
- the amount of food-grade bacteria to be administered is governed by factors affecting efficacy. When administered in feed or drinking water the dosage can be spread over a period of days or even weeks.
- the cumulative effect of lower doses administered over several days may be greater than a single larger dose thereof.
- One or more strains of food-grade bacteria may be administered together.
- a combination of strains may be advantageous because individual subjects may differ as to the strain which is most persistent in a given individual.
- the present invention is also directed to extracts or fragments of food-grade bacterial that may be capable of removing or sequestering toxic compounds from a substance or sample. As shown herein, the inventors found that dead food-grade bacteria may be used to sequester mercury from a sample. As such the present invention is directed to food-grade bacteria fragments capable of binding toxic compounds found in a substance of interest.
- Food-grade bacteria of the present invention may be used as a preventive measure, to prevent a subject not presently carrying a toxic compound, from acquiring the toxic compound by exposure to consumables or environments where the toxic compounds are present. Food grade bacteria of the present invention may also be used to substantially reduce or substantially eliminate toxic compounds from a subject.
- Treatment of a subject carrying the toxic compounds may be accomplished to reduce or eliminate the amount of the toxic compound carried by the subject, by administering the food-grade bacteria, or extracts thereof, to the subject carrying the toxic compound.
- the methods for administering food-grade bacteria may essentially be the same, whether for prevention or treatment.
- the risk of contamination by the undesired toxin may be substantially reduced or substantially eliminated by a combination of prevention and treatment.
- food-grade bacteria of the present invention may be used in methods to filter toxic compounds out of a substance.
- the method may comprise contacting the substance with the food-grade bacteria for a sufficient amount of time, and removing the food-grade bacteria and the toxin from the substance.
- the food-grade bacteria, extracts or fragments of said food-grade bacteria capable of binding to the toxic compounds may, for example, be attached to a filter, or to a solid support, such as an affinity column, and the substance may then be run through the filter or affinity column.
- Food-grade bacteria may also be used, according to another embodiment of the present invention, to feed aquatic animals such as fish and shrimp.
- food-grade bacteria of the present invention may, for example, be added to tanks and ponds containing the aquatic animal.
- the food-grade bacteria used for aquatic animals may be a bacteria that occurs naturally in fresh and sea water environments.
- compositions are preferred.
- One food-grade bacterium may be administered alone or in conjunction with a second, different food-grade bacterium. Any number of different food-grade bacteria may be used in conjunction.
- conjunction with is meant together, substantially simultaneously or sequentially.
- the compositions may be administered in the form of tablet, pill or capsule, for example.
- One preferred form of application involves the preparation of a freeze-dried capsule comprising the composition of the present invention.
- Another preferred form of application involves the preparation of a lyophilized capsule of the present invention.
- Still another preferred form of application involves the preparation of a heat dried capsule of the present invention.
- amount effective is meant an amount of food-grade bacterium or bacteria, e.g., Lactobacillus , high enough to significantly positively modify the condition to be treated but low enough to avoid serious side effects (at a reasonable benefit/risk ratio), within the scope of sound medical judgment.
- An effective amount of Lactobacillus will vary with the particular goal to be achieved, the age and physical condition of the subject being treated, the duration of treatment, the nature of concurrent therapy and the specific Lactobacillus employed. The effective amount of Lactobacillus will thus be the minimum amount which will provide the desired detoxification.
- the food-grade bacteria e.g. Lactobacillus
- the active ingredients which comprise food-grade bacteria may be required to be coated in a material to protect said organisms from the action of enzymes, acids and other natural conditions which may inactivate said organisms.
- they should be coated by, or administered with, a material to prevent inactivation.
- food-grade bacteria may be co-administered with enzyme inhibitors or in liposomes.
- Enzyme inhibitors include pancreatic trypsin inhibitor, diisopropylfluorophosphate (DFP) and trasylol.
- Liposomes include water-in-oil-in-water P40 emulsions as well as conventional and specifically designed liposomes which transport Lactobacilli or their by-products to an internal target of a host subject.
- the food-grade organisms may also be administered parenterally or intraperitoneally.
- Dispersions can also be prepared, for example, in glycerol, liquid polyethylene glycols, and mixtures thereof, and in oils.
- the pharmaceutical forms suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like), suitable mixtures thereof and vegetable oils.
- the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion.
- isotonic agents for example, sugars or sodium chloride.
- Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions are prepared by incorporating the food-grade bacteria in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the various sterilized food-grade bacteria into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
- the preferred methods of preparation are vacuum-drying and the freeze-drying technique which yield a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof. Additional preferred methods of preparation include but are not limited to lyophilization and heat-drying.
- the active compound may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsule, or it may be compressed into tablets designed to pass through the stomach (i.e., enteric coated), or it may be incorporated directly with the food of the diet.
- the food-grade bacteria may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
- the tablets, troches, pills, capsules, and the like, as described above, may also contain the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid, and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin may be added or a flavoring agent such as peppermint, oil or wintergreen or cherry flavoring.
- a binder such as gum tragacanth, acacia, corn starch or gelatin
- excipients such as dicalcium phosphate
- a disintegrating agent such as corn starch, potato starch, alginic acid, and the like
- a lubricant such as magnesium stearate
- a sweetening agent such as sucrose, lactose or saccharin may be added or a
- a syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor.
- any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed.
- the food-grade organism may be incorporated into sustained-release preparations and formulations.
- Dosage unit form refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of the food-grade bacteria calculated to produce the desired preventive or therapeutic effect in association with the required pharmaceutical carrier.
- the specification for the novel dosage unit forms of the invention may be dictated by and may be directly depending on (a) the unique characteristics of the food-grade bacteria and the particular preventive, detoxification or therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such food-grade bacteria for the establishment and maintenance of a healthy flora in the intestinal tract.
- the food-grade organism is compounded for convenient and effective administration in effective amounts with a suitable pharmaceutically or food acceptable carrier in dosage unit form as hereinbefore disclosed.
- a unit dosage form can, for example, contain the principal active compound in an amount approximating 10 9 viable or non-viable, e.g., Lactobacilli , per ml.
- the dosages are determined by reference to the usual dose and manner of administration of the said ingredients.
- the pharmaceutically acceptable carrier may be in the form of milk or portions thereof including yogurt. Skim milk, skim milk powder, non-milk or non-lactose containing products may also be employed.
- the skim milk powder is conventionally suspended in phosphate buffered saline (PBS), autoclaved or filtered to eradicate proteinaceous and living contaminants, then freeze dried heat dried, vacuum dried, or lyophilized.
- PBS phosphate buffered saline
- substances which can serve as pharmaceutical carriers are sugars, such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethycellulose, ethylcellulose and cellulose acetates; powdered tragancanth; malt; gelatin; talc; stearic acids; magnesium stearate; calcium sulfate; calcium carbonate; vegetable oils, such as peanut oils, cotton seed oil, sesame oil, olive oil, corn oil and oil of theobroma; polyols such as propylene glycol, glycerine, sorbitol, manitol, and polyethylene glycol; agar; alginic acids; pyrogen-free water; isotonic saline; cranberry extracts and phosphate buffer solution; skim milk powder; as well as other non-toxic compatible substances used in pharmaceutical formulations such as Vitamin C, estrogen and echinacea, for example.
- the subject may be orally administered a therapeutically effective amount of at least one food-grade bacteria and a pharmaceutically acceptable carrier in accordance with the present invention.
- the food-grade bacteria may be a Lactobacillus .
- the Lactobacillus may be selected from the group comprising the bacteria listed in Table 1.
- Example 1 Demonstration of Removal of Inorganic Lead and Cadmium from an Aqueous Environment
- FIGS. 1A-1B illustrate the ability of food grade Lactobacilli to remove Pb ( FIG. 1A ) and Cd ( FIG. 1B ) from a solution at starting inoculums of 2 ppm and 2.5 ppm for lead and cadmium respectively.
- Pb FIG. 1A
- Cd FIG. 1B
- FIGS. 1A-1B illustrate the ability of food grade Lactobacilli to remove Pb ( FIG. 1A ) and Cd ( FIG. 1B ) from a solution at starting inoculums of 2 ppm and 2.5 ppm for lead and cadmium respectively.
- FIG. 1A 45-50% of Pb was removed from solution while as illustrated in FIG. 1B 40-80% of Cd was removed. Removals of both Pb and Cd were deemed significant (p ⁇ 0.05) by an ANOVA one-way analysis of variance.
- Lactobacilli removed 70-80% of metal in solution while E. coli removal was only 30-50%.
- the amount removed by Lactobacilli compared to E. coli strains and uninoculated control were shown to be significant (P ⁇ 0.05) by an ANOVA one-way analysis of variance.
- the assay was carried out as previously described in Examples 1 and 2. Viable cells of all Lactobacilli were compared to cells that were killed by gamma irradiation at 5.5 Kilo Grays (KG) for 1 hr. Gamma irradiation was used as it kills the cells without destroying cell wall/membrane integrity. Equal inoculums of viable and dead cells were used. With reference to FIG. 3B , live and cells irradiated with gamma rays were able to remove roughly equal amounts of cadmium. However, as illustrated in FIG. 3A , there was a split between the ability of viable or dead cells to bind more lead. The results obtained herein show that binding of metals may likely be a surface associated action not requiring actively metabolic cells. As such, the present invention is also directed to the parts of food-grade bacteria capable of binding heavy metals.
- FIGS. 4A-4C illustrate TEM micrographs of Lactobacillus rhamnosus R37 incubated in 50 mM HEPES-NaOH buffer ( FIG. 4A ) with 1 mM Pb ( FIG. 4B ) and 1 mM HgCl 2 ( FIG. 4C ) added. Numerous deposits are observed throughout the cells incubated with heavy metals ( FIGS. 4B-4C ) however; some smaller deposits are also visible when no metal is added ( FIG. 4A ). The nature of the deposits was confirmed using SEM and EDX analysis.
- FIGS. 5A-5C are SEM micrographs of Lactobacillus rhamnousus R37 incubated in 50 mM HEPES-NaOH buffer ( FIG. 5A ) with 1 mM Pb ( FIG. 5B ) and 1 mM HgCl 2 ( FIG. 5C ) added. Numerous deposits are observed throughout the cells incubated with heavy metals ( FIGS. 5B-5C ) however; some smaller deposits are also visible when no metal is added ( FIG. 5A ).
- FIGS. 6A-6C illustrate energy-dispersive X-ray spectroscopy (EDX) analysis of putative metal deposits in Lactobacillus rhamnosus R37. Osmium coated samples being imaged with SEM were analyzed with EDX to determine the elemental composition of putative metal deposits within the cell.
- FIG. 6A demonstrates the spectrum (bottom) of a portion of cell not containing any visible deposits and mercury was not detected.
- FIG. 6B shows analysis of a large deposit which was determined to contain 36.62% mercury by mass proving cellular sequestration of mercury (see Table 2).
- Lactobacilli were incubated in a 50 mM HEPES buffer for 2 hrs at 37° C. in the presence of metals at a final concentration of 10 mM.
- the assay was carried out by incubating bacteria ( Lactobacillus rhamnousus GR-1) for 2 hrs in a 10 mM metal solution at 37° C. Following incubation the bacteria were diluted 100-fold and filtered through a 0.2 ⁇ m filter to trap bacteria and allow passage of solution. The filters were dried at room temperature for 2 hrs and then coated with 5 nm of osmium tetra oxide. The identification of the metals was confirmed by EDAX X-ray analysis which showed that the metal precipitates were the heavy metals added to solution.
- FIGS. 7A-7C are scanning electron micrographs (SEM) of Lactobacillus rhamnosus GR-1 incubated with ( FIG. 7A ) lead or ( FIG. 7B ) cadmium.
- SEM scanning electron micrographs
- the bright spots observable in the images represent the precipitation of heavy metal particles on the surface and inside the cell.
- FIG. 7C displays the non metal control which is the Lactobacilli without addition of metals, note the absence of precipitate metal particles.
- Caco-2 cells were grown in 12 or 24 well plates for two weeks using supplemented Eagles Minimum Essential Medium (ATCC®) as described above. At two weeks, media was aspirated and cells were washed lightly 2 ⁇ with warm 50 mM HEPES buffer. Bacterial cultures of interest were also grown in 5 mL broth cultures for 22 hrs and washed 2 ⁇ with 50 mM HEPES. Bacterial cells were resuspended to 10 mL in Eagles Minimum Essential Medium (ATCC®) without any Pen/Strep in solution, 400 ⁇ L of media was added to wells in 24 well plates and 900 ⁇ L of media was used in 12 well plates. Bacteria were allowed to incubate with cell line for 2 hr at 37° C.
- ATCC® Eagles Minimum Essential Medium
- metal spiked solutions of Eagles Minimum Essential Medium was made by adding stock concentrations of Pb, Cd or As (Sigma Aldrich®) to the media at desired concentrations.
- ATCC® Eagles Minimum Essential Medium
- the bacterial metal solution was aspirated so that only cells adhering to the Caco-2 cell monolayer remained, the media was replaced with the metal spiked media in addition control wells were set up that either did not have metal in the media and were not incubated with bacterial species. Cells were incubated for 5 hrs in metal spiked media at 37° C.
- Cells were diluted by a factor of 10 by suspending 50 ⁇ L of cells with 450 ⁇ L of Guava Viacount® Reagent (Cat No. 4000-0041) in a clean sample tube, cells were stained for at least 5 min. Stained cells were then analyzed for viability using the Guava ViaCount Assay on the Guava EasyCyte Mini bench top flowcytometer. Cells were separated based on viability forming two distinct populations: live and dead. Populations were analyzed and statistically compared using FlowJo (TreeStarTM) analysis software for flow cytometry data. Cells were analyzed to see differences in viability after exposure to metals in the presence or absence of Lactobacilli.
- FIG. 8 illustrates a flow cytometry analysis of the Caco-2 cell line comparing viability vs. mortality for un treated cells ( FIG. 8A ), Caco-2 cells exposed to cadmium ( FIG. 8B ), Caco-2 cells exposed to Lactobacillus plantarum 14917T ( FIG. 8C ) and Caco-2 cells pretreated with Lactobacillus plantarum 14917T and then exposed to cadmium ( FIG. 8D ). As shown by FIG. 8D addition of Lactobacillus plantarum 14917T before cadmium exposure contributed to increased survival of the cell line then when just exposed to cadmium ( FIG. 8B ).
- Example 7 Viability of Lead and Cadmium Resistant Food Grade Bacteria of the Genus Lactobacillus
- the assay was carried out by inoculating a 200 ⁇ L well of Man Rogosa Sharpe (MRS) medium containing lead or cadmium at a concentration of 100 ppm with an inoculum of 10 7 bacteria from a fresh 24 hrs broth cultures of the Lactobacilli species Lactobacillus rhamnosus GR-1 and Lactobacillus plantarum 14917T. Growth was measured by OD600 for 24 hrs. incubation at 37° C. Growth was measured for 24 hours with readings taken every 30 minutes by optical density measurements at a wavelength of 600 nm. Following the growth assay all species were diluted and drop plated on MRS agar to determine colony forming units (CFU) in solution.
- MRS Man Rogosa Sharpe
- FIGS. 9A-9B show growth of all tested Lactobacilli species in the MRS media with lead ( FIG. 9A ) or cadmium ( FIG. 9B ) at a concentration of 100 ppm.
- Example 8 Demonstration of Removal of Inorganic Mercury from an Aqueous Environment
- FIG. 11 shows the ability of a food grade bacterium to remove MeHg 2+ from solution at a starting inoculum of 1 ppm MeHgCl2. (Error bars ⁇ SEM). As illustrated in FIG. 11 , the Lactobacilli removed 23.2% of a 1 ppm mercury inoculum (p ⁇ 0.05 by an unpaired t-test).
- Example 10 Inorganic Mercury Removal by Live and Dead Lactobacillus rhamnosus DN116-060
- the assay was carried out as previously described in Example 9 at a concentration of 500 ppb HgCl 2 .
- Viable cells of Lactobacillus rhamnosus DN116-010 were compared to cells that were killed by heating at 80° C. for 10 minutes at an inoculum equivalent to the final cell density of viable cells.
- FIG. 12 illustrates the ability of live and dead Lactobacillus rhamnosus DN116-060 to remove Hg 2+ from solution at a starting inoculum of 500 ppb HgCl 2 .
- viable cells were capable of removing significantly more mercury than heat killed cells (p ⁇ 0.05 by unpaired t-test) suggesting that there is a passive sequestering of mercury as well as potential metabolic detoxification.
- Assay was carried out as previously described in Example 9 across a spectrum of HgCl 2 concentrations. Growth was measured after 24 hours at 37° C. by the optical density of cultures at a wavelength of 600 nm. A spectrum of resistances to mercury were observed in both species demonstrating that resistance to mercury is a variable trait among food grade bacteria.
- FIG. 13B illustrates three Lactobacillus rhamnosus strains showing a distinctly higher resistance as compared to the rest of the strains.
- Example 1 The assay described in Example 1 was carried out using a selection of Lactobacillus rhamnosus strains of increased resistance and increased sensitivity to mercury.
- FIGS. 15A-15B illustrate removal of mercury from solution by a selection of Lactobacillus rhamnosus strains of increased resistance (R) and strains of increased sensitivity (S) to mercury at HgCl 2 concentrations of 0.5 ppm ( FIG. 15A ) and 1 ppb ( FIG. 15B ). Resistant strains removed significantly more mercury from solution than their sensitive counterparts (p ⁇ 0.05 as determined by ANOVA with Bonferroni post test [ FIG. 15A ] and un-paired t-test [ FIG. 15B ]). (Error bars ⁇ SEM)
- Example 14 Removal of Arsenite and Arsenate from an Aqueous Environment
- the assay was carried out by inoculating a 1 ppm (9.08 ⁇ 1018 free atoms) arsenite solution (HEPES buffer) with 1 ⁇ 10 9 CFU/mL of selected Lactobacilli .
- the solutions were incubated for 5 hrs at 37° C.; following incubation cells were removed by centrifugation at 5, 000 g.
- the total arsenic remaining in solution was analyzed via inductively coupled plasma-mass spectrometry (ICP-MS).
- Lactobacilli removed 11-13% of the total arsenic which was determined by looking at differences in concentrations in total free atoms in solution vs. bound to each species.
- the assay was carried out by inoculating a 100 ppm arsenite solution of HEPES buffer with 1 ⁇ 10 9 CFU/mL of the selected Lactobacilli .
- the solutions were incubated for 5 hrs at 37° C.; following incubation cells were removed by centrifugation at 5,000 g.
- the total arsenic remaining in solution was analyzed via inductively coupled plasma-mass spectrometery (ICP-MS).
- Example 17 Demonstration of Removal of Malathion and Parathion from Aqueous Environment by Probiotic Bacteria
- Lactobacillus rhamnosus GR-1 was able to remove 20% of the malathion from solution ( FIG. 19A ) and 50% of the parathion ( FIG. 19B ).
- Example 18 Demonstration of Removal of Malathion and Parathion Simultaneously by a Probiotic Bacterium
- Lactobacillus rhamnosus GR-1 was able to remove 50% of the malathion from solution and 50% of the parathion.
- Example 19 Demonstration of Removal of Pesticides by a Panel of Food Grade Bacteria and Some E. coli Species
- FIG. 21A illustrates that the Lactobacilli were able to remove 35-60% of malathion, while E. coli was able to remove 10-25% of malathion.
- FIG. 21B illustrates that the Lactobacilli and E. coli were able to remove 55-70% of parathion.
- Example 20 Demonstration of Removal of Endotoxins by a Panel of Food Grade Bacteria
- Endotoxins are well known toxins responsible for sepsis and death. They are produced by a number of Gram negative bacteria and to date few effective treatments have been developed. Other potent toxins produced by bacteria include the fatal Shiga toxin produced by E. coli 0157:H5, and TcdA and TcdB toxins from Clostridium difficile both of which damage the human colonic mucosa and are potent cytotoxic enzymes. Deaths from C. difficile toxins have become a major concern in North American hospitals and care homes. Probiotic therapy has shown great promise in preventing infections caused by E. coli 0157:H7 and C. difficile.
- Alkaline phosphatase levels can be measured in feces and blood as it has been shown that up-regulation of this enzyme can detoxify endotoxins in the gut and improve gut permeability.
- a pig model is used for this assay.
- C. difficile toxins will be detected from stool by a commercially available enzyme-linked fluorescence immunoassay.
- Example 21 Demonstration of Removal of Aflatoxin by a Panel of Food Grade Bacteria
- Aflatoxin (a hepatic carcinogen) is important contributors to disease, albeit risk of exposure to the mainstay population in N. America is low. Aflatoxin B1 has been included because probiotics can have an effect against it, and such results have implications for many sub-populations in the US (eg large farming communities) and beyond (eg Middle East, Argentina).
- the aflatoxin will be measured from blood by affinity column cleanup and LC-MS/MS fluorescence.
- Example 22 Demonstration of Removal of Heterocyclic Aromatic Amines (HAA) by a Panel of Food Grade Bacteria
- Heterocyclic aromatic amines are found in food (eg processed meat) and cause diet-related mutagenesis which plays an etiologic role in chronic diseases, including cardiovascular disease and cancer. Their direct association with cancer is low, but the potential for them to be inhibited by probiotics makes them worth studying, as a positive detox effect provides a good consumer message.
- Acrylamide is made industrially but is highly regulated due to its neurotoxicity. It naturally forms in certain foods, particularly plant-based foods that are rich in carbohydrates and low in protein, during processing or cooking at high temperatures (French fries, potato chips). Also found heavily in cigarette smoke. Acrylamide is monitored and studied by Health Canada, but no levels have been established on what is toxic/safe, so it's tough to set a ‘limit’ or even tell in a study what would be considered dangerous. It has a link to causing cancer and information on how much will cause this effect is not known.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Emergency Management (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Business, Economics & Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The present invention relates to food-grade bacteria and methods for removing toxic compounds, including lead, cadmium, mercury, arsenic and pesticides, from contaminated environments or substances.
Description
- This application is a divisional of U.S. patent application Ser. No. 14/390,685 filed Oct. 3, 2014, which in turn is a national stage application under 35 U.S.C. 371 of International Application No. PCT/CA2013/000328, filed 5 Apr. 2013, which in turn claims the benefit under 35 U.S.C. 119(e) of U.S. Provisional Ser. No. 61/620,796, filed Apr. 5, 2012, the contents of each of which are hereby incorporated by reference into the present disclosure.
- The present invention relates to food grade bacteria for improving detoxification. More particularly, the present invention relates to food grade bacteria, or extracts thereof, and to methods of using food grade bacteria or extracts thereof to reduce uptake of ingested toxic compounds and to methods of sequestering toxic compounds from the environment to which the food-grade bacteria is exposed to.
- Humans and animals in general, are exposed to many toxic compounds that contaminate the environment, food chain, water supply and various items that are part of everyday life. These range in number, type and exposure from ingredients in toothpaste and shampoos to drugs and pathogens in well-water. Amongst Canadian First Nation and Inuit populations, environmental toxins are risk factors for other highly prevalent diseases, especially
type 2 diabetes [Sharp D. Environmental toxins, a potential risk factor for diabetes among Canadian Aboriginals. Int J Circumpolar Health. 2009; 68(4):316-26]. A large over-the-counter consumer market has arisen under the guise of ‘detox’, but most of the products have no rationale or clinical evidence to support their use. The concept of detox has great appeal to consumers, both the health-conscious and others concerned with the growing number of stories in the media about pollution and diseases related to toxic substances. Thus, there is substantial interest in this area, few effective products and a growing need. - The replenishment or boosting of the beneficial organisms through administration of probiotics has become feasible in Canada relatively recently, and has led to much interest amongst consumer and healthcare professionals. Indeed, probiotics are one of the fastest growing food segments in North America. However, gaining insight into the mechanisms by which indigenous microbes and exogenous probiotics affect the subject has been limited.
- Probiotic Lactobacilli and bifidobacteria have been shown to help manage several gut pathologies. For example, U.S. Pat. No. 6,641,808 disclosing the use of Lactobacilli for the treatment of obesity; U.S. Pat. No. 5,531,988, discloses a mixture of an immunoglobulin and a bacterium, such as Lactobacilli or bifidobacterium or mixtures thereof, that may be used to treat diarrhea, constipation, and gas/cramps; U.S. Pat. No. 6,080,401 discloses a combination of probiotics having Lactobacillus acidophilus and Bifidobacterium bifidus and herbal preparations for aiding in weight loss, and so forth.
- The ability of probiotic products to ameliorate toxins has been much less studied, but nevertheless has some foundation. For example, Lactobacilli and/or bifidobacteria have been found to alter the subject's intestinal metabolic signature [Ndagijimana, M. Laghi L, Vitali B, Placucci G, Brigidi P, Guerzoni M E. Effect of synbiotic food consumption on human gut metabolic profiles evaluated by 1H nuclear magnetic resonance spectroscopy. Int J Food Microbiol. 2009; 134: 147-153]; bind to aflatoxin (Lactobacillus strains) [Hernandez-Mendoza A, Garcia H S, Steele J L. Screening of Lactobacillus casei strains for their ability to bind aflatoxin B1. Food Chem Toxicol. 2009; 47(6):1064-8]; and detoxify or bind and negate other mycotoxins (B. animalis) [Fuchs S, Sontag G, Stidl R, Ehrlich V, Kundi M, Knasmüller S. Detoxication of patulin and ochratoxin A, two abundant mycotoxins, by lactic acid bacteria. Food Chem Toxicol. 2008; 46(4):1398-407].
- In summary, the problem associated with toxic compounds is real, and of growing concern to consumers.
- Heavy metal toxicity is one of the largest health risks in the 21st century. Consumption of lead and cadmium through environmental exposure and diet has been directly responsible for poor health outcomes including: impaired neurological function and loss of IQ, osteoporosis, lung and kidney cancer.
- Heavy metals such as lead and cadmium are present in the natural environment, and therefore many bacteria over time have developed mechanisms of resistance to these metals which generally include actively precipitating and sequestering the metals intra/extra cellular or the active efflux of metals out of the cell cytoplasm. Non-food grade bacteria have been investigated for their use in sequestration and detoxification of heavy metals and have shown success (JS Singh et al. Genetically engineered bacteria: An emerging tool for environmental remediation and future research perspectives. Gene. July 2011. 40 (1-2):1-9); Rajkumar et al. Potential of siderophore-producing bacteria for improving heavy metal phytoextraction. Trends Biotechnol. March 2010. 28 (3):142-149).
- Mercury is one of the most toxic substances known to man and its consumption by a subject is linked to poor health outcomes including altered neurological development in children. Yet, North Americans and Europeans are estimated to consume 6.7 μg daily of inorganic mercury and methylmercury (World Health Organization, 1991).
- Mercury is present in the natural environment, and as such, many bacteria have adopted mechanisms of resistance to it, which generally reduce mercury levels in the surrounding environment. Many non-food grade bacteria have been investigated for their use in sequestration and detoxification of mercury and mercury compounds in the environment, however the application of food grade bacteria has not been demonstrated to date.
- Arsenic is a metalloid element which commonly comes in two oxidation states: arsenate (As V) and arsenite (As III). Arsenic is found distributed globally often in the earth's crust, it is highly soluble in water and is found in high concentrations in ground water. Arsenic toxicity has been linked to a number of cases and is known to cause organ failure, cancer and death. Main routes of exposure is through ingestion via diet, often arsenic contaminated waters are used for irrigation of farmland resulting in accumulation of the metal in plants and food.
- Pesticides such as malathion and parathion fall into the class of organophosphate compounds and act as cholinesterase inhibitors. Malathion is one of the most widely used pesticides in the U.S., and parathion use has recently been limited and is not used in many developed nations due to high toxicity. However, produce imports still consistently detect levels of parathion on produce and it is used in some rare instances in North America.
- Major routes of public exposure is through consumption via diet. Agricultural workers and industrial workers are at increased risk of exposure through work place by absorption or inhalation if safety protocols not properly followed.
- In view of the problems associated to the exposure of any of the above toxic compounds, it would be advantageous to provide for food grade bacteria that can sequester toxic compounds, including heavy metals, mercury, arsenic, pesticides, such as malathion and parathion, or a combination thereof, from the gastrointestinal tract of a subject to reduce the amount of the toxic compound available to be absorbed by the subject, while detoxifying the toxic compounds directly reduces the toxicity of toxic compounds available to be absorbed by the subject.
- It is an object of the present invention to provide for food-grade bacteria or extracts thereof for the removal and/or neutralization of toxic products from an environment or from a substance to which the food-grade bacteria is exposed to, that solve the deficiencies inherent in traditional detoxification treatments. The present invention provides methods and uses of food grade bacteria for removal and/or neutralization of toxic products found in the internal environment of animals, in the environment to which the animal is exposed or in substance ingested or to be ingested by the animals that may avoid adverse side effects, is reasonable in cost, and may be beneficial in reducing the risk of diseases related to said toxic products. Further, the present invention is relatively easy to manufacture and deliver to a subject.
- It is an object of the present invention to provide for food grade bacteria, or extracts thereof, to detoxify and/or sequester toxic compounds, including heavy metals, mercury, arsenic and pesticides, with the application of reducing a subject's toxic compounds exposure and uptake.
- As such, in one embodiment, the present invention provides food-grade bacteria or extracts thereof for removing of toxic compounds from a substance or environment to which the food-grade bacteria is exposed to.
- In one embodiment, the present invention provides for a composition comprising a food-grade bacteria and a suitable carrier, whereby the composition comprises an effective dose of the food-grade bacteria to remove a toxic compound from a substance or environment to which the food-grade bacteria is exposed to.
- In one embodiment of the composition of the present invention, the therapeutically effective dose is at least about 1×109 of the food-grade bacteria per milliliter or less of the suitable carrier.
- In another embodiment of the composition of the present invention, the suitable carrier is a carbohydrate-containing medium.
- In another embodiment of the composition of the present invention, the carbohydrate-containing medium is a milk-based product.
- In another embodiment of the composition of the present invention, the toxic compound is selected from the group consisting of lead, cadmium, mercury, arsenic, malathion and parathion.
- In another embodiment of the composition of the present invention, the food-grade bacteria are provided dead or live.
- In another embodiment of the composition of the present invention, the food-grade bacteria are provided as an extract.
- In another embodiment of the composition of the present invention, the composition comprises a combination of two or more different species of food-grade bacteria.
- In another embodiment of the composition of the present invention, the composition comprises a combination of two or more strains of Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus crispatus, Lactobacillus fermentum, Lactobacillus johnsonii, Lactobacillus plantarum, Lactobacillus reuteri, and Lactobacillus amylovorus.
- In another embodiment of the composition of the present invention, the food-grade bacteria is selected from the group of food-grade bacteria listed in Table 1 shown bellow. It is mentioned that a bacteria strain of interest is the Lactobacillus rhamnosus strain deposited, according to the Budapest Treaty, at CNCM (Collection Nationale de Cultures de Microorganismes, 25 rue du Docteur Roux, Paris) on Mar. 5, 2013, under the accession number CNCM 1-4719. This strain is also referred to as “DN 116-060” or R37.
- In another embodiment of the composition of the present invention, the environment is an aqueous environment.
- In another embodiment, the present invention is a composition, the composition including food-grade bacteria, a carrier and an animal's feed, wherein the food-grade bacteria is capable of removing a toxic compound from a substance or environment to which the food-grade bacteria is exposed to and the food-grade bacteria comprises a bacterial isolate selected from the group consisting of the food-grade bacteria listed in Table 1 or any combination thereof.
- In one embodiment, the present invention is a method for reducing a subject uptake of toxic compounds consumed by the subject, the method including administering to the subject an effective dose of a food-grade bacteria capable of sequestering the toxic compound consumed by the subject.
- In another embodiment, a method for removing a toxic compound from a substance or environment which is contaminated or suspected of being contaminated with the toxic compound is provided, the method including contacting the substance or environment with food-grade bacteria capable of removing the toxic compound from the substance or the environment.
- In one embodiment, the present invention is a method of reducing the toxic effects of a toxic compound in a subject, the method including: administering to the subject a therapeutically effective amount of a food-grade bacteria capable of removing the toxic compound from a substance or environment.
- In one embodiment of the previous methods of the present invention the toxic compound is selected from the group consisting of lead, cadmium, mercury, arsenic, malathion and parathion.
- In another embodiment of the previous methods of the present invention the food-grade bacteria are provided dead or live.
- In another embodiment of the previous methods of the present invention the food-grade bacteria are provided as an extract.
- In another embodiment of the previous methods of the present invention the food-grade bacteria comprise a combination of two or more different species of food-grade bacteria.
- In another embodiment of the previous methods of the present invention the composition comprises a combination of two or more strains of Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus crispatus, Lactobacillus fermentum, Lactobacillus johnsonii, Lactobacillus plantarum, Lactobacillus reuteri, and Lactobacillus amylovorus
- In another embodiment of the previous methods of the present invention the food grade bacteria are selected from the group of food-grade bacteria listed in Table 1.
- In one embodiment, the present invention is a method of obtaining a strain of Lactobacillus capable of removing a toxic compound from an environment, the method including a step of mutagenesis or genetic transformation of the Lactobacilus.
- In one embodiment, the present invention is a method for obtaining a cell fraction capable of removing a toxic compound from an environment, including the steps of: a) culturing a Lactobacillus strain, and b) recovering the cell fraction from the culture in step a).
- In one embodiment of the last two methods the toxic compound is selected from the group consisting of lead, cadmium, mercury, arsenic, malathion and parathion. In another embodiment Lactobacillus is provided dead or live. In another embodiment the Lactobacillus is provided as an extract. In another embodiment the Lactobacillus includes a combination of two or more different strains. In another embodiment, the Lactobacillus is selected from the group of Lactobacilli listed in Table 1.
- In one embodiment, the present invention is a use of a food grade bacteria for the removal of a toxic compound from a substance or an environment.
- In one embodiment of the use of the food grade bacteria, the toxic compound is selected from the group consisting of lead, cadmium, mercury, arsenic, malathion and parathion.
- In another embodiment of the use of the food grade bacteria, the food-grade bacteria are provided dead or live.
- In another embodiment of the use of the food grade bacteria, the food-grade bacteria are provided as an extract.
- In another embodiment of the use of the food grade bacteria, the food grade bacteria are provided as a combination of two or more different species of food-grade bacteria.
- In another embodiment of the use of the food grade bacteria, the food grade bacteria are provided as two or more strains of Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus crispatus, Lactobacillus fermentum, Lactobacillus johnsonii, Lactobacillus plantarum, Lactobacillus reuteri, and Lactobacillus amylovorus.
- In another embodiment of the use of the food grade bacteria, the food-grade bacteria is selected from the group of food-grade bacteria listed in Table 1.
- In another embodiment, the present invention provides for a method for removing a toxic compound from a substance which is suspected of being contaminated with said toxic compound comprising contacting the substance with food-grade bacteria or extract thereof capable of removing the toxic compound from the substance.
- In another embodiment, the present invention provides for a method of reducing the toxic effects of a toxic compound in a subject, the method comprising: administering to the subject a therapeutically effective amount of food-grade bacteria of Table 1 or any combination thereof.
- In one embodiment, the present invention provides for a method of obtaining a strain of Lactobacillus capable of removing a toxic compound from an environment, the method includes a step of mutagenesis or genetic transformation of the Lactobacilus.
- In another embodiment, the present invention is a method for obtaining a cell fraction capable of removing a toxic compound from an environment. The method, in one embodiment, includes the steps of: a) culturing a Lactobacillus strain, and b) recovering the cell fraction from the culture in step a).
- In one embodiment of the methods of the present invention, the food-grade bacteria comprise a combination of two or more different species of food-grade bacteria.
- In one embodiment of the present invention, the food grade bacteria is a Lactobacillus.
- In one aspect of the present invention the toxic compound includes a heavy metal.
- In another aspect of the present invention, the toxic compound includes a heavy metal and the food-grade bacteria comprise dead bacteria.
- In another aspect of the present invention, the toxic compound includes a heavy metal and the food-grade bacteria comprise live bacteria.
- In one another of the present invention, the toxic compound includes a heavy metal and the food-grade bacteria comprise a mixture of dead bacteria and live bacteria.
- In another aspect of the present invention the heavy metal is cadmium.
- In another aspect of the present invention the heavy metal is lead.
- In another aspect of the present invention the toxic compound includes mercury.
- In another aspect of the invention the mercury is inorganic mercury.
- In another aspect of the invention the mercury is organic mercury.
- In one aspect of the present invention, the toxic compound includes mercury and the food-grade bacteria comprise dead bacteria.
- In one aspect of the present invention, the toxic compound includes mercury and the food-grade bacteria comprise live bacteria.
- In one aspect of the present invention, the toxic compound includes mercury and the food-grade bacteria comprise a mixture of dead bacteria and live bacteria.
- In another aspect of the present invention the toxic compound includes arsenic.
- In one aspect of the present invention, the toxic compound includes arsenic and the food-grade bacteria comprise dead bacteria.
- In one aspect of the present invention, the toxic compound includes arsenic and the food-grade bacteria comprise live bacteria.
- In one aspect of the present invention, the toxic compound includes arsenic and the food-grade bacteria comprise a mixture of dead bacteria and live bacteria.
- In another aspect of the present invention the toxic compound includes a pesticide.
- In one aspect of the present invention, the toxic compound includes a pesticide and the food-grade bacteria comprise dead bacteria.
- In one aspect of the present invention, the toxic compound includes a pesticide and the food-grade bacteria comprise live bacteria.
- In one aspect of the present invention, the toxic compound includes a pesticide and the food-grade bacteria comprise a mixture of dead bacteria and live bacteria.
- In another aspect of the present invention the pesticide is selected from malathion or parathion.
- In another aspect of the present invention, the toxic compound includes endotoxins.
- In another aspect of the present invention, the toxic compound includes heterocyclic aromatic amines.
- In another aspect of the present invention, the toxic compound includes acrylamide.
- The present invention will become more fully understood from the detailed description given herein and from the accompanying drawings, which are given by way of illustration only and do not limit the intended scope of the invention.
-
FIG. 1A is a graph illustrating the ability of food grade Lactobacilli to remove lead (Pb) from a solution (error bars±SEM). -
FIG. 1B is a graph illustrating the ability of food grade Lactobacilli to remove cadmium (Cd) from a solution (error bars±SEM). -
FIG. 2A is a graph illustrating the ability of food grade Lactobacilli to remove lead (Pb) from a solution compared to E. coli (error bars±SEM). -
FIG. 2B is a graph illustrating the ability of food grade Lactobacilli to remove cadmium (Cd) compared to E. coli (error bars±SEM). -
FIG. 3A is a graph illustrating the ability of live and dead food grade Lactobacilli to remove lead (Pb) from a solution (error bars±SEM). -
FIG. 3B is a graph illustrating the ability of live and dead food grade Lactobacilli to remove cadmium (Cd) from a solution (error bars±SEM). -
FIGS. 4A-4C are TEM microphotographs of Lactobacillus rhamnosus R37 incubated with a control buffer without the addition of metals (FIG. 4A ), lead (FIG. 4B ), and mercury (FIG. 4C ). -
FIGS. 5A-5C are scanning electron micrographs of Lactobacillus rhamnosus R37 incubated with a control buffer without the addition of metals (FIG. 5A ), lead (FIG. 5B ), and mercury (FIG. 5C ). -
FIG. 6A is a scanning electron micrograph of Lactobacillus rhamnosus R37 (top) and a corresponding energy-dispersive X-ray spectrum of a portion of a cell not containing visible deposits. -
FIG. 6B is a scanning electron micrograph of Lactobacillus rhamnosus R37 (top) and a corresponding energy-dispersive X-ray spectrum of a portion of a cell containing visible deposits. -
FIGS. 7A-7C are scanning electron microphotographs of Lactobacillus rhamnosus GR-1 incubated with lead (FIG. 7A ), cadmium (FIG. 7B ), and a control without the addition of metals (FIG. 7C ). -
FIGS. 8A-8D are flow cytometry analysis of Caco-2 cell line comparing viability vs. mortality of untreated cells (FIG. 8A ), cells exposed to cadmium (FIG. 8B ), cells exposed toLactobacillus plantarum 14917T (FIG. 8C ), and cells exposed toLactobacillus plantarum 14917T and then exposed to cadmium (FIG. 8D ). -
FIG. 9A is a graph illustrating the growth of a number of Lactobacilli species in Man Rogosa Sharpe (MRS) media having lead. -
FIG. 9B is a graph illustrating the growth of a number of Lactobacilli species in MRS media having cadmium. -
FIG. 10A is a graph illustrating the ability of a food grade bacterium of the present invention to remove Hg2+ from a solution having a 1 part per million (ppm) Hg2+ inoculum (error bars±SEM; * signifies significant (p<0.05) difference by an unpaired T-test). -
FIG. 10B is a graph illustrating the ability of a food grade bacterium of the present invention to remove Hg2+ from a solution having a 15 part per billion (ppb) Hg2+ inoculum (error bars±SEM; * signifies significant (p<0.05) difference by an unpaired T-test). -
FIG. 11 is a graph illustrating the ability of a food grade bacterium of the present invention to remove organic mercury from a solution (error bars±SEM; * signifies significant (p<0.05) difference by an unpaired T-test). -
FIG. 12 is a graph illustrating the ability of live and dead food grade bacterium of the present invention to remove inorganic mercury from a solution (error bars±SEM; * signifies significant (p<0.05) difference by an unpaired T-test). -
FIGS. 13A-13B are graphs illustrating variability of mercury resistance within a group of food grade bacteria of the genus Lactobacillus.FIG. 13A illustrates growth of different strains of Lactobacillus casei in a gradient of Hg2+ andFIG. 13B illustrates growth of different strains of Lactobacillus rhamnosus in a gradient of Hg2+. -
FIG. 14 is a graph illustrating twenty-four hour time course of mercury removal by Lactobacillus rhamnosus R37 and GR-1 in HEPES-NaOH supplemented with 1 μg/mL HgCl2 incubated at 37° C. -
FIGS. 15A-15B are graphs illustrating removal of mercury from solution by a selection of Lactobacillus rhamnosus strains of increased resistance (R) and strains of increased sensitivity (S) to mercury at HgCl2 concentrations of 0.5 ppm (FIG. 15A ) and 1 ppb (FIG. 15B ). -
FIG. 16 is a graph illustrating the ability of food grade bacteria and E. coli species to remove As (III) and As (V) from solution at starting inoculums of 10 ppm. -
FIG. 17 is a graph illustrating the ability of food grade bacteria to remove As (III) from solution at a starting inoculums of 1 ppm. (Error bars±SEM). -
FIG. 18 is a graph illustrating the ability of Lactobacilli to remove As (III) from solution at starting inoculums of 100 ppm. -
FIGS. 19A-19B are graphs depicting the ability of probiotic bacteria to remove malathion (FIG. 19A ) and parathion (FIG. 19B ) from solution. Starting inoculums for malathion and parathion are 5 μg and 0.5 μg respectively. (Error bars±SEM). -
FIG. 20 is a graph illustrating the ability of a probiotic bacterium to remove both malathion and parathion from solution simultaneously. Malathion original concentration was 5 μg while parathion was 0.5 μg. (Error bars±SEM). -
FIGS. 21A-21B are graphs depicting the ability of food grade bacteria and E. coli to remove malathion (FIG. 21A ) or parathion (FIG. 21B ) from solution. Starting inoculums of pesticides for malathion and parathion was 10 mg/L and 3 mg/L respectively. (Error bars±SEM). - Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Also, unless indicated otherwise, except within the claims, the use of “or” includes “and” and vice versa. Non-limiting terms are not to be construed as limiting unless expressly stated or the context clearly indicates otherwise (for example “including”, “having” and “comprising” typically indicate “including without limitation”). Singular forms including in the claims such as “a”, “an” and “the” include the plural reference unless expressly stated otherwise.
- The expression “food grade bacteria” refers to any bacteria, alive or dead, that have no harmful effect on human health or that have a GRAS (generally recognized as safe) status. Such bacteria maybe selected from the group consisting of Lactobacilli and Bacilli. Non-limiting examples of food-grade bacteria particularly suitable for the purpose of the present invention are listed in Table 1.
- The term “probiotic” as used in this document refers to food-grade bacteria which perform beneficial functions to subject organisms when they are present and alive in viable form in the subject organisms.
- “Food production animal” is used herein to describe any animal that is prepared and used for human consumption. A food production animal can be, but not limited to, a ruminant animal such as beef and dairy cattle, pigs, lamb, chicken, turkey or any other fowl, or aquatic animals including shrimp, lobster or fish used for human consumption.
- As used herein, the term “removing a toxic compound from a substance or environment” refers to a removal of one or more toxic compounds that can be tested as described in at least one of the examples below.
- “Subject” or “subjects” are used herein to describe a member of the animal kingdom, including food production animals and humans.
- The present invention also encompasses mutant strains or genetically transformed strains derived from a parent strain. These mutant or genetically transformed strains can be strains wherein one or more endogenous gene(s) of the parent strain has (have) been mutated, for instance to modify some of its metabolic properties (e.g., its ability to ferment sugars, its resistance to acidity, its survival to transport in the gastrointestinal tract, its post-acidification properties or its metabolite production). They can also be strains resulting from the genetic transformation of the parent strain by one or more gene(s) of interest, for instance in order to confer to said genetically transformed strains additional physiological features, or to allow it to express proteins of therapeutic or vaccinal interest that one wishes to administer through said strains. These strains can be obtained from a strain by means of the conventional techniques for random or site-directed mutagenesis and genetic transformation of Lactobacilli, such as those described by Gury et al. (2004) or by Perea Vélez et al., 2007, or by means of the technique known as “genome shuffling” (Patnaik et al., 2002 and Wang et al., 2007).
- A subject of the present invention is also cell fractions which can be obtained from a Lactobacillus strain. They are in particular DNA preparations or bacterial wall preparations obtained from cultures of said strain. They may also be culture supernatants or fractions of these supernatants. By way of example, cell-free supernatant (CFS) of one Lactobacillus strain can be obtained using the method for obtaining a CFS from another Lactobacillus strain.
- A subject of the present invention is also a method for obtaining a cell fraction, comprising the steps of:
- a) culturing a Lactobacillus strain, and
b) obtaining and/or recovering the cell fraction from the culture in step a). - In compositions of the invention, said strain can be used in the form of whole bacteria which may be living or dead. Alternatively, said strain can be used in the form of a bacterial lysate or in the form of bacterial fractions; the bacterial fractions suitable for this use can be chosen, for example, by testing their properties on mercury removal from an aqueous environment. Preferably the bacterial cells are present as living, viable cells.
- In one embodiment, the present invention relates to food-grade bacterial or extracts thereof, including probiotics, capable of removing or sequestering toxic compounds from an environment to which the food-grade bacteria is exposed to, or from a substance which may have or may be suspected of having the toxic compound. Substances may include edible compositions, such as vegetable-based foods or animal-based foods, and may also include drinkable solutions, including water, milk, syrups, extracts and other beverages. Substances may also include raw agricultural products used to produce foods and drinkable solutions. As such, the present invention relates also to methods of using the food-grade bacteria of the present invention to prevent the uptake of toxic compounds by a subject, or in methods to filter toxic compounds out of substances prior to exposing a subject to said substances. The environment may include an aqueous environment, such as the gastro-intestinal tract of a subject, or the environment in which the subject resides, such as a pond.
- The food grade bacteria may be any type of bacteria that may be capable of removing toxic compounds from foods or solutions that may be consumed by a subject, or from ingredients used in the manufacture of said foods or solutions. Table 1 includes food-grade bacteria that may be used with the present invention. In a preferred aspect, the food-grade bacteria may be aerobically, microaerophilically or anaerobically grown and may be selected from the group consisting of the food-grade bacteria of Table 1. Administration of the food-grade bacteria, or extract thereof, to a subject may be accomplished by any method likely to introduce the organisms into the gastro-intestinal tract of the subject. The bacteria can be mixed with a carrier and applied to liquid or solid feed or to drinking water. The carrier material should be non-toxic to the subject. When dealing with live food-grade bacteria, the carrier material should also be non-toxic to the food-grade bacteria. When dealing with live food-grade bacteria the carrier, preferably, may include an ingredient that promotes viability of the bacteria during storage. The food-grade bacteria may also be formulated as an inoculant paste to be directly injected into a subject's mouth. The formulation may include added ingredients to improve palatability, improve shelf-life, impart nutritional benefits, and the like. If a reproducible and measured dose is desired, the food-grade bacteria can be administered by a cannula or syringe. The amount of food-grade bacteria to be administered is governed by factors affecting efficacy. When administered in feed or drinking water the dosage can be spread over a period of days or even weeks. The cumulative effect of lower doses administered over several days may be greater than a single larger dose thereof. One or more strains of food-grade bacteria may be administered together. A combination of strains may be advantageous because individual subjects may differ as to the strain which is most persistent in a given individual.
- The present invention is also directed to extracts or fragments of food-grade bacterial that may be capable of removing or sequestering toxic compounds from a substance or sample. As shown herein, the inventors found that dead food-grade bacteria may be used to sequester mercury from a sample. As such the present invention is directed to food-grade bacteria fragments capable of binding toxic compounds found in a substance of interest.
- Food-grade bacteria of the present invention may be used as a preventive measure, to prevent a subject not presently carrying a toxic compound, from acquiring the toxic compound by exposure to consumables or environments where the toxic compounds are present. Food grade bacteria of the present invention may also be used to substantially reduce or substantially eliminate toxic compounds from a subject.
- Treatment of a subject carrying the toxic compounds may be accomplished to reduce or eliminate the amount of the toxic compound carried by the subject, by administering the food-grade bacteria, or extracts thereof, to the subject carrying the toxic compound.
- The methods for administering food-grade bacteria may essentially be the same, whether for prevention or treatment. By routinely administering an effective dose to a subject, the risk of contamination by the undesired toxin may be substantially reduced or substantially eliminated by a combination of prevention and treatment.
- In one embodiment, food-grade bacteria of the present invention may be used in methods to filter toxic compounds out of a substance. The method, in one embodiment, may comprise contacting the substance with the food-grade bacteria for a sufficient amount of time, and removing the food-grade bacteria and the toxin from the substance. To accomplish this filtration of toxic compounds from a substance, the food-grade bacteria, extracts or fragments of said food-grade bacteria capable of binding to the toxic compounds, may, for example, be attached to a filter, or to a solid support, such as an affinity column, and the substance may then be run through the filter or affinity column.
- Food-grade bacteria may also be used, according to another embodiment of the present invention, to feed aquatic animals such as fish and shrimp. In one embodiment, food-grade bacteria of the present invention may, for example, be added to tanks and ponds containing the aquatic animal. Preferably the food-grade bacteria used for aquatic animals, may be a bacteria that occurs naturally in fresh and sea water environments.
- Although this invention is not intended to be limited to any particular mode of application, oral administration of the compositions are preferred. One food-grade bacterium may be administered alone or in conjunction with a second, different food-grade bacterium. Any number of different food-grade bacteria may be used in conjunction. By “in conjunction with” is meant together, substantially simultaneously or sequentially. The compositions may be administered in the form of tablet, pill or capsule, for example. One preferred form of application involves the preparation of a freeze-dried capsule comprising the composition of the present invention. Another preferred form of application involves the preparation of a lyophilized capsule of the present invention. Still another preferred form of application involves the preparation of a heat dried capsule of the present invention.
- By “amount effective” as used herein is meant an amount of food-grade bacterium or bacteria, e.g., Lactobacillus, high enough to significantly positively modify the condition to be treated but low enough to avoid serious side effects (at a reasonable benefit/risk ratio), within the scope of sound medical judgment. An effective amount of Lactobacillus will vary with the particular goal to be achieved, the age and physical condition of the subject being treated, the duration of treatment, the nature of concurrent therapy and the specific Lactobacillus employed. The effective amount of Lactobacillus will thus be the minimum amount which will provide the desired detoxification.
- A decided practical advantage is that the food-grade bacteria, e.g. Lactobacillus, may be administered in a convenient manner such as by the oral, intravenous (where non-viable), or suppository (vaginal or rectal) routes. Depending on the route of administration, the active ingredients which comprise food-grade bacteria may be required to be coated in a material to protect said organisms from the action of enzymes, acids and other natural conditions which may inactivate said organisms. In order to administer food-grade bacteria by other than parenteral administration, they should be coated by, or administered with, a material to prevent inactivation. For example, food-grade bacteria may be co-administered with enzyme inhibitors or in liposomes. Enzyme inhibitors include pancreatic trypsin inhibitor, diisopropylfluorophosphate (DFP) and trasylol. Liposomes include water-in-oil-in-water P40 emulsions as well as conventional and specifically designed liposomes which transport Lactobacilli or their by-products to an internal target of a host subject.
- The food-grade organisms may also be administered parenterally or intraperitoneally. Dispersions can also be prepared, for example, in glycerol, liquid polyethylene glycols, and mixtures thereof, and in oils.
- The pharmaceutical forms suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like), suitable mixtures thereof and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion. In many cases it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions are prepared by incorporating the food-grade bacteria in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized food-grade bacteria into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and the freeze-drying technique which yield a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof. Additional preferred methods of preparation include but are not limited to lyophilization and heat-drying.
- When the food-grade bacteria are suitably protected as described above, the active compound may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsule, or it may be compressed into tablets designed to pass through the stomach (i.e., enteric coated), or it may be incorporated directly with the food of the diet. For oral therapeutic administration, the food-grade bacteria may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
- The tablets, troches, pills, capsules, and the like, as described above, may also contain the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid, and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin may be added or a flavoring agent such as peppermint, oil or wintergreen or cherry flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills or capsules or Lactobacilli in suspension may be coated with shellac, sugar or both.
- A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the food-grade organism may be incorporated into sustained-release preparations and formulations.
- It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of the food-grade bacteria calculated to produce the desired preventive or therapeutic effect in association with the required pharmaceutical carrier. The specification for the novel dosage unit forms of the invention may be dictated by and may be directly depending on (a) the unique characteristics of the food-grade bacteria and the particular preventive, detoxification or therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such food-grade bacteria for the establishment and maintenance of a healthy flora in the intestinal tract.
- The food-grade organism is compounded for convenient and effective administration in effective amounts with a suitable pharmaceutically or food acceptable carrier in dosage unit form as hereinbefore disclosed. A unit dosage form can, for example, contain the principal active compound in an amount approximating 109 viable or non-viable, e.g., Lactobacilli, per ml. In the case of compositions containing supplementary ingredients such as prebiotics, the dosages are determined by reference to the usual dose and manner of administration of the said ingredients.
- The pharmaceutically acceptable carrier may be in the form of milk or portions thereof including yogurt. Skim milk, skim milk powder, non-milk or non-lactose containing products may also be employed. The skim milk powder is conventionally suspended in phosphate buffered saline (PBS), autoclaved or filtered to eradicate proteinaceous and living contaminants, then freeze dried heat dried, vacuum dried, or lyophilized.
- Some other examples of substances which can serve as pharmaceutical carriers are sugars, such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethycellulose, ethylcellulose and cellulose acetates; powdered tragancanth; malt; gelatin; talc; stearic acids; magnesium stearate; calcium sulfate; calcium carbonate; vegetable oils, such as peanut oils, cotton seed oil, sesame oil, olive oil, corn oil and oil of theobroma; polyols such as propylene glycol, glycerine, sorbitol, manitol, and polyethylene glycol; agar; alginic acids; pyrogen-free water; isotonic saline; cranberry extracts and phosphate buffer solution; skim milk powder; as well as other non-toxic compatible substances used in pharmaceutical formulations such as Vitamin C, estrogen and echinacea, for example. Wetting agents and lubricants such as sodium lauryl sulfate, as well as coloring agents, flavoring agents, lubricants, excipients, tabletting agents, stabilizers, anti-oxidants and preservatives, can also be present.
- Accordingly, the subject may be orally administered a therapeutically effective amount of at least one food-grade bacteria and a pharmaceutically acceptable carrier in accordance with the present invention. The food-grade bacteria may be a Lactobacillus. The Lactobacillus may be selected from the group comprising the bacteria listed in Table 1.
-
TABLE 1 Strains Tested For Ability to Degrade or Sequester Toxic Compounds Species Strain Code 1 Strain Code 2Lactobacillus casei Shirota YIT 9029 FERM BP-1366 Lactobacillus casei ATCC 393 Lactobacillus crispatus ATCC 33323 Lactobacillus fermentum ATCC 11739 Lactobacillus johnsonii DSM 20553 Lactobacillus plantarum ATCC 14917 Lactobacillus rhamnosus ATCC 27773 Lactobacillus reuteri RC-14 ATCC 55845 Lactobacillus amylovorus LAB Lactobacillus rhamnosus GG ATCC 53013 Lactobacillus rhamnosus GR-1 ATCC 55826 Lactobacillus rhamnosus HN001 Lactobacillus rhamnosus R37 DN 116-0060 Lactobacillus rhamnosus R38 DN 116-0063 Lactobacillus rhamnosus R22 DN 116-0009 Lactobacillus rhamnosus R17 DN 116-0136 Lactobacillus rhamnosus R29 DN 116-0064 Lactobacillus rhamnosus R3 DN 116-0061 Lactobacillus rhamnosus R10 DN 116-0032 Lactobacillus rhamnosus R11 DN 116-0141 Lactobacillus casei C3 DN 114-0017 Lactobacillus casei C8 DN 114-0022 Lactobacillus casei C11 DN 114-0125 Lactobacillus casei C26 DN 114-0074 Lactobacillus casei C6 DN 114-0226 Lactobacillus casei C20 DN 114-0037 Lactobacillus casei C29 DN 114-0230 Lactobacillus casei C13 DN 114-0126 Lactobacillus casei C28 DN 114-0189 Lactobacillus casei C31 DN 114-0227 Lactobacillus casei C10 DN 114-0223 Lactobacillus casei C1 DN 114-0001 - The above disclosure generally describes the present invention. Changes in form and substitution of equivalents are contemplated as circumstances may suggest or render expedient. Although specific terms have been employed herein, such terms are intended in a descriptive sense and not for purposes of limitation.
- The examples are described for the purposes of illustration and are not intended to limit the scope of the invention.
- 1 mL inoculums of 24 hour cultures of Lactobacillus rhamnosus GR-1,
Lactobacillus casei 393T, Lactobacillus johnosonii 20553 andLactobacillus plantarum 14917T at cell concentrations of approx. 1×109 CFU/mL were added to a 50 mM HEPES buffer containing Pb or Cd and incubated for 5 hours at 37° C. Following incubation, cells were removed by centrifugation at 5, 000 G. The total metal concentration in the supernatant was analyzed via Inductively Coupled Plasma-Mass Spectrometry (ICP-MS). -
FIGS. 1A-1B illustrate the ability of food grade Lactobacilli to remove Pb (FIG. 1A ) and Cd (FIG. 1B ) from a solution at starting inoculums of 2 ppm and 2.5 ppm for lead and cadmium respectively. Depending on the species/strain of Lactobacilli examined and the metal environment there was variation in removal. As illustrated inFIG. 1A 45-50% of Pb was removed from solution while as illustrated inFIG. 1B 40-80% of Cd was removed. Removals of both Pb and Cd were deemed significant (p<0.05) by an ANOVA one-way analysis of variance. - 1 mL inoculums of 24 hour cultures of Lactobacillus rhamnosus GR-1, Lactobacillus rhamnosus GG, E. coli Col and
E. coli 25922 at cell concentrations of approx. 1×109 CFU/mL were added to a 50 mM HEPES buffer containing Pb or Cd and incubated for 5 hours at 37° C. Following incubation, cells were removed by centrifugation at 5, 000 G. The total metal concentration in the supernatant was analyzed via Inductively Coupled Plasma-Mass Spectrometry (ICP-MS). As illustrated inFIGS. 2A-2B , for both Pb (FIG. 2A ) and Cd (FIG. 2B ), Lactobacilli removed 70-80% of metal in solution while E. coli removal was only 30-50%. The amount removed by Lactobacilli compared to E. coli strains and uninoculated control were shown to be significant (P<0.05) by an ANOVA one-way analysis of variance. - In this example, the ability of live and dead Lactobacilli to remove lead (
FIG. 3A ) cadmium and (FIG. 3B ) from solution at a starting inoculums of 3 ppm was tested. - The assay was carried out as previously described in Examples 1 and 2. Viable cells of all Lactobacilli were compared to cells that were killed by gamma irradiation at 5.5 Kilo Grays (KG) for 1 hr. Gamma irradiation was used as it kills the cells without destroying cell wall/membrane integrity. Equal inoculums of viable and dead cells were used. With reference to
FIG. 3B , live and cells irradiated with gamma rays were able to remove roughly equal amounts of cadmium. However, as illustrated inFIG. 3A , there was a split between the ability of viable or dead cells to bind more lead. The results obtained herein show that binding of metals may likely be a surface associated action not requiring actively metabolic cells. As such, the present invention is also directed to the parts of food-grade bacteria capable of binding heavy metals. -
FIGS. 4A-4C illustrate TEM micrographs of Lactobacillus rhamnosus R37 incubated in 50 mM HEPES-NaOH buffer (FIG. 4A ) with 1 mM Pb (FIG. 4B ) and 1 mM HgCl2 (FIG. 4C ) added. Numerous deposits are observed throughout the cells incubated with heavy metals (FIGS. 4B-4C ) however; some smaller deposits are also visible when no metal is added (FIG. 4A ). The nature of the deposits was confirmed using SEM and EDX analysis. -
FIGS. 5A-5C are SEM micrographs of Lactobacillus rhamnousus R37 incubated in 50 mM HEPES-NaOH buffer (FIG. 5A ) with 1 mM Pb (FIG. 5B ) and 1 mM HgCl2 (FIG. 5C ) added. Numerous deposits are observed throughout the cells incubated with heavy metals (FIGS. 5B-5C ) however; some smaller deposits are also visible when no metal is added (FIG. 5A ). -
FIGS. 6A-6C illustrate energy-dispersive X-ray spectroscopy (EDX) analysis of putative metal deposits in Lactobacillus rhamnosus R37. Osmium coated samples being imaged with SEM were analyzed with EDX to determine the elemental composition of putative metal deposits within the cell.FIG. 6A demonstrates the spectrum (bottom) of a portion of cell not containing any visible deposits and mercury was not detected.FIG. 6B shows analysis of a large deposit which was determined to contain 36.62% mercury by mass proving cellular sequestration of mercury (see Table 2). - Similar results were also obtained for GR-1, R3, R39, Lactobacillus casei C3 showing mercury in the cell.
-
TABLE 2 Control Suspected Hg deposit Element Weight % Atomic % Element Weight % Atomic % Carbon 74.44 87.03 Carbon 39.67 70.99 Oxygen 11.75 10.32 Nitrogen 7.51 11.52 Sulfur 4.50 1.97 Oxygen 8.51 11.44 Osmium 9.30 0.69 Phosphorus 1.23 0.85 Totals 100.00 100.00 Sulfur 0.97 0.65 Osmium 5.50 0.62 Mercury 36.62 3.92 Totals 100.00 100.00 - Lactobacilli were incubated in a 50 mM HEPES buffer for 2 hrs at 37° C. in the presence of metals at a final concentration of 10 mM. The assay was carried out by incubating bacteria (Lactobacillus rhamnousus GR-1) for 2 hrs in a 10 mM metal solution at 37° C. Following incubation the bacteria were diluted 100-fold and filtered through a 0.2 μm filter to trap bacteria and allow passage of solution. The filters were dried at room temperature for 2 hrs and then coated with 5 nm of osmium tetra oxide. The identification of the metals was confirmed by EDAX X-ray analysis which showed that the metal precipitates were the heavy metals added to solution.
-
FIGS. 7A-7C are scanning electron micrographs (SEM) of Lactobacillus rhamnosus GR-1 incubated with (FIG. 7A ) lead or (FIG. 7B ) cadmium. The bright spots observable in the images represent the precipitation of heavy metal particles on the surface and inside the cell.FIG. 7C displays the non metal control which is the Lactobacilli without addition of metals, note the absence of precipitate metal particles. - Caco-2 cells were grown in 12 or 24 well plates for two weeks using supplemented Eagles Minimum Essential Medium (ATCC®) as described above. At two weeks, media was aspirated and cells were washed lightly 2× with warm 50 mM HEPES buffer. Bacterial cultures of interest were also grown in 5 mL broth cultures for 22 hrs and washed 2× with 50 mM HEPES. Bacterial cells were resuspended to 10 mL in Eagles Minimum Essential Medium (ATCC®) without any Pen/Strep in solution, 400 μL of media was added to wells in 24 well plates and 900 μL of media was used in 12 well plates. Bacteria were allowed to incubate with cell line for 2 hr at 37° C. During incubation period metal spiked solutions of Eagles Minimum Essential Medium (ATCC®) was made by adding stock concentrations of Pb, Cd or As (Sigma Aldrich®) to the media at desired concentrations. Following incubation period the bacterial metal solution was aspirated so that only cells adhering to the Caco-2 cell monolayer remained, the media was replaced with the metal spiked media in addition control wells were set up that either did not have metal in the media and were not incubated with bacterial species. Cells were incubated for 5 hrs in metal spiked media at 37° C.
- Following this incubation, media was removed by aspiration and discarded. Cells were washed once gently with warm HEPES buffer and then removed from the wells using 500 ul of 0.25% (w/v) trypsin until cells detached from flask. 500 μL of cell media was added to stop trypsin reaction and total volume of each well was transferred into separate sterile 1.5 mL centrifuge tubes (Diamed®). The cell suspension was mixed by pipetting to avoid formation of bubbles. Cells were centrifuged in a bench top microcentrifuge for 2 mins at 120 RPM, supernatant was discarded and cells were suspended in 1×PBS. Cells were diluted by a factor of 10 by suspending 50 μL of cells with 450 μL of Guava Viacount® Reagent (Cat No. 4000-0041) in a clean sample tube, cells were stained for at least 5 min. Stained cells were then analyzed for viability using the Guava ViaCount Assay on the Guava EasyCyte Mini bench top flowcytometer. Cells were separated based on viability forming two distinct populations: live and dead. Populations were analyzed and statistically compared using FlowJo (TreeStar™) analysis software for flow cytometry data. Cells were analyzed to see differences in viability after exposure to metals in the presence or absence of Lactobacilli.
-
FIG. 8 illustrates a flow cytometry analysis of the Caco-2 cell line comparing viability vs. mortality for un treated cells (FIG. 8A ), Caco-2 cells exposed to cadmium (FIG. 8B ), Caco-2 cells exposed toLactobacillus plantarum 14917T (FIG. 8C ) and Caco-2 cells pretreated withLactobacillus plantarum 14917T and then exposed to cadmium (FIG. 8D ). As shown byFIG. 8D addition ofLactobacillus plantarum 14917T before cadmium exposure contributed to increased survival of the cell line then when just exposed to cadmium (FIG. 8B ). - The assay was carried out by inoculating a 200 μL well of Man Rogosa Sharpe (MRS) medium containing lead or cadmium at a concentration of 100 ppm with an inoculum of 107 bacteria from a fresh 24 hrs broth cultures of the Lactobacilli species Lactobacillus rhamnosus GR-1 and
Lactobacillus plantarum 14917T. Growth was measured by OD600 for 24 hrs. incubation at 37° C. Growth was measured for 24 hours with readings taken every 30 minutes by optical density measurements at a wavelength of 600 nm. Following the growth assay all species were diluted and drop plated on MRS agar to determine colony forming units (CFU) in solution. -
FIGS. 9A-9B show growth of all tested Lactobacilli species in the MRS media with lead (FIG. 9A ) or cadmium (FIG. 9B ) at a concentration of 100 ppm. - A 1% inoculum of a 24 hour culture of Lactobacillus rhamnosus DN116-060 was added to de Man Rogosa Sharpe (MRS) broth containing HgCl2 and incubated for 24 hours at 37° C. Following incubation, cells were removed by centrifugation at 5,000 g. The total mercury concentration in the supernatant was analyzed via cold vapor atomic absorption spectroscopy (CVAAS). As illustrated in
FIGS. 10A-10B , the Lactobacilli removed 94.4% of a 1 part per million (ppm) mercury inoculum (FIG. 10A ) and 85% of a 15 part per billion (ppb) inoculum (FIG. 10B ). Both removals were deemed significant (p<0.05) by an unpaired T-test. - A 1% inoculum of a 24 hour culture of Lactobacillus rhamnosus DN116-060 was added to de Man Rogosa Sharpe (MRS) broth containing MeHgCl2 and incubated for 24 hours at 37° C. Following incubation, cells were removed by centrifugation at 5,000 g. The total mercury concentration in the supernatant was analyzed via cold vapor atomic absorption spectroscopy (CVAAS).
-
FIG. 11 shows the ability of a food grade bacterium to remove MeHg2+ from solution at a starting inoculum of 1 ppm MeHgCl2. (Error bars±SEM). As illustrated inFIG. 11 , the Lactobacilli removed 23.2% of a 1 ppm mercury inoculum (p<0.05 by an unpaired t-test). - The assay was carried out as previously described in Example 9 at a concentration of 500 ppb HgCl2. Viable cells of Lactobacillus rhamnosus DN116-010 were compared to cells that were killed by heating at 80° C. for 10 minutes at an inoculum equivalent to the final cell density of viable cells.
-
FIG. 12 illustrates the ability of live and dead Lactobacillus rhamnosus DN116-060 to remove Hg2+ from solution at a starting inoculum of 500 ppb HgCl2. As shown inFIG. 12 , viable cells were capable of removing significantly more mercury than heat killed cells (p<0.05 by unpaired t-test) suggesting that there is a passive sequestering of mercury as well as potential metabolic detoxification. - Assay was carried out as previously described in Example 9 across a spectrum of HgCl2 concentrations. Growth was measured after 24 hours at 37° C. by the optical density of cultures at a wavelength of 600 nm. A spectrum of resistances to mercury were observed in both species demonstrating that resistance to mercury is a variable trait among food grade bacteria.
-
FIGS. 13A-13B illustrate the growth of Lactobacillus casei (n=38) (FIG. 13A ) and Lactobacillus rhamnosus (n=40) (FIG. 13B ) in a gradient of Hg2+ measured by OD600 after 24 hours incubation at 37° C. Each set of connected points represents one strain. Resistance is a strain variable trait resulting in a spectrum of resistance profiles in both species.FIG. 13B illustrates three Lactobacillus rhamnosus strains showing a distinctly higher resistance as compared to the rest of the strains. - Twenty-four hour time course of mercury removal by Lactobacillus rhamnosus R37 (in viable and heat killed form) and GR-1 in HEPES-NaOH supplemented with 1 μg/mL HgCl2 incubated at 37° C. With reference to
FIG. 14 , sequestration activity is not instantaneous and reaches a maximum after 12 h in Lactobacillus rhamnosus R37 while maximal removal was observed at 24 hours in the case of Lactobacillus rhamnosus GR-1. - The assay described in Example 1 was carried out using a selection of Lactobacillus rhamnosus strains of increased resistance and increased sensitivity to mercury.
-
FIGS. 15A-15B illustrate removal of mercury from solution by a selection of Lactobacillus rhamnosus strains of increased resistance (R) and strains of increased sensitivity (S) to mercury at HgCl2 concentrations of 0.5 ppm (FIG. 15A ) and 1 ppb (FIG. 15B ). Resistant strains removed significantly more mercury from solution than their sensitive counterparts (p<0.05 as determined by ANOVA with Bonferroni post test [FIG. 15A ] and un-paired t-test [FIG. 15B ]). (Error bars±SEM) - Bacterial cultures were grown for 24 hrs in preferential media; Man Rogoas Sharpe (MRS) broth for Lactobacilli and Luria-Bertani (LB) broth for E. coli. Cells were centrifuged, washed and re-suspended in PBS. 1 mL aliquouts were distributed between sample tubes containing 9 mL of PBS buffer spiked with arsenic, 1 mL of MRS or LB broth was added to sample tubes. Cells were incubated for 5 hrs at 37° C.; following incubation cells were removed by centrifugation at 5, 000 g. The total arsenic remaining in solution was analyzed via inductively coupled plasma-mass spectrometry (ICP-MS). As illustrated in
FIG. 16 Lactobacilli were able to remove 50-60% of As (III) and As (V) while E. coli DH5a was less effective. - The assay was carried out by inoculating a 1 ppm (9.08×1018 free atoms) arsenite solution (HEPES buffer) with 1×109 CFU/mL of selected Lactobacilli. The solutions were incubated for 5 hrs at 37° C.; following incubation cells were removed by centrifugation at 5, 000 g. The total arsenic remaining in solution was analyzed via inductively coupled plasma-mass spectrometry (ICP-MS).
- As shown in
FIG. 17 and Table 3, Lactobacilli removed 11-13% of the total arsenic which was determined by looking at differences in concentrations in total free atoms in solution vs. bound to each species. -
TABLE 3 Species % Removed L. rhamnosus GR-1 13 L. johnsonii 20553 11 L. casei 393T11 L. plantarum 14917T11 - The assay was carried out by inoculating a 100 ppm arsenite solution of HEPES buffer with 1×109 CFU/mL of the selected Lactobacilli. The solutions were incubated for 5 hrs at 37° C.; following incubation cells were removed by centrifugation at 5,000 g. The total arsenic remaining in solution was analyzed via inductively coupled plasma-mass spectrometery (ICP-MS).
- As shown in
FIG. 18 , all Lactobacilli showed ability to remove near 70% of arsenic from solution compared to the untreated control sample. Species to species variation in amount of arsenic able to remove was low and not significant. - Bacterial broth cultures of Lactobacillus rhamnosus GR-1 were grown for 24 hrs in Man Rogosa Sharpe (MRS) broth. Cells were collected, washed and re-suspended in a 1×PBS buffer. 1 mL of cell suspension was transferred into sample tube containing a 50:50 mixture of HEPES buffer having the pesticides and MRS. Starting inoculums of pesticides for malathion and parathion was 5 μg/L of HEPES buffer and 0.5 μg/L of HEPES buffer respectively. Samples were incubated for 5 hrs at 37° C. Following incubation cells were removed by centrifugation at 5, 000 g. The remaining pesticide in solution was analyzed via gas chromatography-mass spec (GC-MS) and values were compared to untreated controls.
- With reference to
FIGS. 19A-19B , Lactobacillus rhamnosus GR-1 was able to remove 20% of the malathion from solution (FIG. 19A ) and 50% of the parathion (FIG. 19B ). - Bacterial broth cultures of Lactobacillus rhamnosus GR-1 were grown for 24 hrs in Man Rogosa Sharpe (MRS) broth. Cells were collected, washed and re-suspended in a 1×PBS buffer. 1 mL of cell suspension was transferred into sample tube containing a 50:50 mixture of HEPES buffer having the pesticides and MRS. Starting inoculums of pesticides for malathion and parathion was 5 μg/L of HEPES buffer and 0.5 μg/L of HEPES buffer respectively. Samples were incubated for 5 hrs at 37° C. Following incubation cells were removed by centrifugation at 5, 000 g. The remaining pesticide in solution was analyzed via gas chromatography-mass spec (GC-MS) and values were compared to untreated controls.
- As shown in
FIG. 20 , Lactobacillus rhamnosus GR-1 was able to remove 50% of the malathion from solution and 50% of the parathion. - Bacterial broth cultures of Lactobacilli were grown for 24 hrs in Man Rogosa Sharpe (MRS) broth, E. coli species were grown for 24 hours in Lucella Broth (LB). Cells were collected, washed and re-suspended in a 1×PBS buffer. 1 mL of cell suspension was transferred into sample tubes containing a 50:50 mixture of HEPES buffer having the pesticide and MRS or LB. Starting inoculums of pesticides for malathion and parathion was 10 mg/L of HEPES buffer and 3 mg/L of HEPES buffer respectively. Samples were incubated for 5 hrs at 37° C. Following incubation cells were removed by centrifugation at 5, 000 g. The remaining pesticide in solution was analyzed via gas chromatography-mass spec (GC-MS) and values were compared to untreated controls.
-
FIG. 21A illustrates that the Lactobacilli were able to remove 35-60% of malathion, while E. coli was able to remove 10-25% of malathion.FIG. 21B illustrates that the Lactobacilli and E. coli were able to remove 55-70% of parathion. - Endotoxins are well known toxins responsible for sepsis and death. They are produced by a number of Gram negative bacteria and to date few effective treatments have been developed. Other potent toxins produced by bacteria include the fatal Shiga toxin produced by E. coli 0157:H5, and TcdA and TcdB toxins from Clostridium difficile both of which damage the human colonic mucosa and are potent cytotoxic enzymes. Deaths from C. difficile toxins have become a major concern in North American hospitals and care homes. Probiotic therapy has shown great promise in preventing infections caused by E. coli 0157:H7 and C. difficile.
- Alkaline phosphatase levels (activity and protein) can be measured in feces and blood as it has been shown that up-regulation of this enzyme can detoxify endotoxins in the gut and improve gut permeability. A pig model is used for this assay. C. difficile toxins will be detected from stool by a commercially available enzyme-linked fluorescence immunoassay.
- Aflatoxin (a hepatic carcinogen) is important contributors to disease, albeit risk of exposure to the mainstay population in N. America is low. Aflatoxin B1 has been included because probiotics can have an effect against it, and such results have implications for many sub-populations in the US (eg large farming communities) and beyond (eg Middle East, Argentina).
- The aflatoxin will be measured from blood by affinity column cleanup and LC-MS/MS fluorescence.
- Heterocyclic aromatic amines (HAA) are found in food (eg processed meat) and cause diet-related mutagenesis which plays an etiologic role in chronic diseases, including cardiovascular disease and cancer. Their direct association with cancer is low, but the potential for them to be inhibited by probiotics makes them worth studying, as a positive detox effect provides a good consumer message.
- They will be measured from urine and blood samples using HPLC.
- Acrylamide is made industrially but is highly regulated due to its neurotoxicity. It naturally forms in certain foods, particularly plant-based foods that are rich in carbohydrates and low in protein, during processing or cooking at high temperatures (French fries, potato chips). Also found heavily in cigarette smoke. Acrylamide is monitored and studied by Health Canada, but no levels have been established on what is toxic/safe, so it's tough to set a ‘limit’ or even tell in a study what would be considered dangerous. It has a link to causing cancer and information on how much will cause this effect is not known.
- Acrylamide will be detected by HPLC.
Claims (19)
1.-35. (canceled)
36. A method for reducing a subject's uptake of toxic compounds consumed by the subject, the method comprising administering to the subject a Lactobacillus capable of sequestering the toxic compound consumed by the subject wherein the Lactobacillus is selected from: Lactobacillus reuteri RC-14, Lactobacillus casei 21052, Lactobacillus casei 393T, Lactobacillus rhamnosus GR-1, Lactobacillus rhamnosus R3, Lactobacillus rhamnosus R37, Lactobacillus johnsonii 20553, Lactobacillus plantarum 14917T, or any combination thereof.
37. The method of claim 36 , wherein the toxic compound is selected from the group consisting of: lead, cadmium, arsenic, malathion and parathion.
38. The method of claim 36 , wherein the Lactobacillus is provided in a viable form.
39. The method of claim 36 , wherein the Lactobacillus is provided in a non-viable form.
40. The method of claim 36 , wherein the Lactobacillus is provided as an extract.
41. The method of claim 36 , wherein the Lactobacillus comprise a combination of two or more different strains of Lactobacillus.
42. The method of claim 36 , wherein the lactobacillus is provided in a composition comprising the Lactobacillus and a suitable carrier.
43. The method of claim 42 , wherein the carrier is a milk-based product.
44. The method of claim 42 , wherein the composition comprises a combination of two or more strains of Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus crispatus, Lactobacillus fermentum, Lactobacillus johnsonii, Lactobacillus plantarum, Lactobacillus reuteri, and Lactobacillus amylovorus.
45. A method for reducing in a subject gastrointestinal uptake of toxic compounds consumed by the subject through edible or drinkable substances contaminated with the toxic compounds, the method comprising administering to the subject a Lactobacillus, wherein the Lactobacillus is selected from: Lactobacillus reuteri RC-14, Lactobacillus casei 21052, Lactobacillus casei 393T, Lactobacillus rhamnosus GR-1, Lactobacillus rhamnosus R3, Lactobacillus rhamnosus R37, Lactobacillus johnsonii 20553, Lactobacillus plantarum 14917T, or any combination thereof.
46. The method of claim 45 , wherein the toxic compound is selected from the group consisting of: lead, cadmium, arsenic, malathion and parathion.
47. The method of claim 45 , wherein the Lactobacillus is provided in a viable form.
48. The method of claim 45 , wherein the Lactobacillus is provided in a non-viable form.
49. The method of claim 45 , wherein the Lactobacillus is provided as an extract.
50. The method of claim 45 , wherein the Lactobacillus comprise a combination of two or more different strains of Lactobacillus.
51. The method of claim 45 , wherein the lactobacillus is provided in a composition comprising the Lactobacillus and a suitable carrier.
52. The method of claim 51 , wherein the carrier is a milk-based product.
53. The method of claim 51 , wherein the composition comprises a combination of two or more strains of Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus crispatus, Lactobacillus fermentum, Lactobacillus johnsonii, Lactobacillus plantarum, Lactobacillus reuteri, and Lactobacillus amylovorus.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/676,021 US20200140806A1 (en) | 2012-04-05 | 2019-11-06 | Food grade bacteria for the removal of toxic compounds |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261620796P | 2012-04-05 | 2012-04-05 | |
PCT/CA2013/000328 WO2013149333A1 (en) | 2012-04-05 | 2013-04-05 | Food grade bacteria for the removal of toxic compounds |
US201414390685A | 2014-10-03 | 2014-10-03 | |
US16/676,021 US20200140806A1 (en) | 2012-04-05 | 2019-11-06 | Food grade bacteria for the removal of toxic compounds |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/390,685 Division US10487305B2 (en) | 2012-04-05 | 2013-04-05 | Food grade bacteria for the removal of toxic compounds |
PCT/CA2013/000328 Division WO2013149333A1 (en) | 2012-04-05 | 2013-04-05 | Food grade bacteria for the removal of toxic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200140806A1 true US20200140806A1 (en) | 2020-05-07 |
Family
ID=48471060
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/390,685 Active US10487305B2 (en) | 2012-04-05 | 2013-04-05 | Food grade bacteria for the removal of toxic compounds |
US14/390,018 Active US9540609B2 (en) | 2012-04-05 | 2013-04-05 | Lactobacillus rhamnosus food grade bacteria |
US16/676,021 Abandoned US20200140806A1 (en) | 2012-04-05 | 2019-11-06 | Food grade bacteria for the removal of toxic compounds |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/390,685 Active US10487305B2 (en) | 2012-04-05 | 2013-04-05 | Food grade bacteria for the removal of toxic compounds |
US14/390,018 Active US9540609B2 (en) | 2012-04-05 | 2013-04-05 | Lactobacillus rhamnosus food grade bacteria |
Country Status (6)
Country | Link |
---|---|
US (3) | US10487305B2 (en) |
EP (2) | EP2833898B1 (en) |
CN (2) | CN104540934A (en) |
CA (1) | CA2869566C (en) |
RU (1) | RU2639547C2 (en) |
WO (2) | WO2013149333A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10487305B2 (en) * | 2012-04-05 | 2019-11-26 | London Health Sciences Centre Research Inc. | Food grade bacteria for the removal of toxic compounds |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
PL3031931T3 (en) * | 2014-12-12 | 2018-05-30 | Compagnie Gervais Danone | Lactobacillus rhamnosus food grade bacteria |
CN104489489B (en) * | 2015-01-12 | 2017-05-03 | 湖南农业大学 | Method for reducing heavy metal cadmium in rice by utilizing mixed fermentation of lactobacillus and saccharomycetes |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
CN106616042A (en) * | 2016-12-23 | 2017-05-10 | 江南大学 | Lactobacillus plantarum feed and application thereof |
PL233582B1 (en) * | 2017-08-21 | 2019-11-29 | Politechnika Lodzka | Lactic bacterial strain of Lactobacillus rhamnosus |
CN109207405B (en) * | 2018-10-22 | 2021-04-27 | 江苏省家禽科学研究所 | Cadmium-resistant lactic acid bacteria and application thereof |
CN109260645B (en) * | 2018-10-31 | 2021-07-02 | 湖南中茂生物科技有限公司 | Method for removing residual pesticide in plant-derived flavonoid extract |
CN109527339A (en) * | 2018-11-30 | 2019-03-29 | 东北农业大学 | A method of utilizing patulin in Lactobacillus rhamnosus removal fluid sample |
CN110317758A (en) * | 2019-07-19 | 2019-10-11 | 河南广安生物科技股份有限公司 | Double toxin antidotes of a kind of broiler chicken and preparation method thereof |
CN110591988B (en) * | 2019-11-01 | 2021-05-14 | 四川农业大学 | Lactobacillus rhamnosus753 and application thereof, silage additive and silage |
CN112708583B (en) * | 2021-01-29 | 2022-05-17 | 重庆第二师范学院 | Lactobacillus fermentum LF-SCHY34 and application thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5531988A (en) | 1994-10-28 | 1996-07-02 | Metagenics, Inc. | Bacteria and immunoglobulin-containing composition for human gastrointestinal health |
US6080401A (en) | 1998-11-19 | 2000-06-27 | Reddy; Malireddy S. | Herbal and pharmaceutical drugs enhanced with probiotics |
ID30071A (en) * | 1998-12-11 | 2001-11-01 | Urex Biotech Inc | PROVISION OF ORAL LACTOBACILLUS FOR TREATMENT AND PREVENTION OF UROGENTAL INFECTIONS |
US6641808B1 (en) | 1999-09-22 | 2003-11-04 | Lacpro Industries, Llc | Composition for treatment of obesity |
TW588109B (en) * | 2000-07-29 | 2004-05-21 | Tcell Biotechnology Food Co Lt | Lactobacillus rhamnosus strain and uses thereof |
WO2007009568A1 (en) * | 2005-07-20 | 2007-01-25 | Unilever N.V. | Edible product containing beneficial bacteria |
RU2332993C2 (en) * | 2006-10-19 | 2008-09-10 | ООО "Научно-технический центр "Промбезопасность-Оренбург" | Method for protecting human body from adverse influences of environment and composition to this effect |
CN100522852C (en) * | 2007-06-20 | 2009-08-05 | 上海裕麒环境技术服务有限公司 | Method for circulating and reutilizing sludge during process of sewage |
CN101333502A (en) * | 2007-06-27 | 2008-12-31 | 上海泓宝绿色水产科技发展有限公司 | Process for preparing emergency strain and repairing aquaculture environment |
US20090029447A1 (en) * | 2007-07-26 | 2009-01-29 | West Virginia University | Process for removing mercury from air or water |
FR2928935B1 (en) * | 2008-03-19 | 2011-05-20 | Gervais Danone Sa | STRAIN OF LACTOBACILLUS RHAMNOSUS. |
US20150064263A1 (en) * | 2010-05-25 | 2015-03-05 | David Kossor | Compositions and methods for reduction of mercury toxicity |
US10487305B2 (en) * | 2012-04-05 | 2019-11-26 | London Health Sciences Centre Research Inc. | Food grade bacteria for the removal of toxic compounds |
CN102872475B (en) * | 2012-09-26 | 2015-04-15 | 天津市伯曼生物科技有限公司 | Biological agent for deodorizing and reducing chromium and preparation method thereof |
-
2013
- 2013-04-05 US US14/390,685 patent/US10487305B2/en active Active
- 2013-04-05 US US14/390,018 patent/US9540609B2/en active Active
- 2013-04-05 RU RU2014143979A patent/RU2639547C2/en active
- 2013-04-05 EP EP13771919.1A patent/EP2833898B1/en active Active
- 2013-04-05 EP EP13724404.2A patent/EP2834377A1/en not_active Ceased
- 2013-04-05 WO PCT/CA2013/000328 patent/WO2013149333A1/en active Application Filing
- 2013-04-05 CN CN201380029689.4A patent/CN104540934A/en active Pending
- 2013-04-05 WO PCT/IB2013/052739 patent/WO2013150497A1/en active Application Filing
- 2013-04-05 CN CN201380029656.XA patent/CN104755090B/en not_active Expired - Fee Related
- 2013-04-05 CA CA2869566A patent/CA2869566C/en active Active
-
2019
- 2019-11-06 US US16/676,021 patent/US20200140806A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2833898A1 (en) | 2015-02-11 |
US10487305B2 (en) | 2019-11-26 |
EP2833898A4 (en) | 2015-12-09 |
RU2639547C2 (en) | 2017-12-21 |
EP2834377A1 (en) | 2015-02-11 |
RU2014143979A (en) | 2016-05-27 |
CN104755090A (en) | 2015-07-01 |
CA2869566C (en) | 2022-08-30 |
US20150079236A1 (en) | 2015-03-19 |
CN104755090B (en) | 2020-10-20 |
CN104540934A (en) | 2015-04-22 |
CA2869566A1 (en) | 2013-10-10 |
WO2013149333A1 (en) | 2013-10-10 |
US20150191691A1 (en) | 2015-07-09 |
US9540609B2 (en) | 2017-01-10 |
EP2833898B1 (en) | 2018-11-14 |
WO2013150497A1 (en) | 2013-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200140806A1 (en) | Food grade bacteria for the removal of toxic compounds | |
de Melo Pereira et al. | How to select a probiotic? A review and update of methods and criteria | |
Zhai et al. | Screening of lactic acid bacteria with potential protective effects against cadmium toxicity | |
EP2848681B1 (en) | Isolation, identification and characterization of strains with probiotic activity from the faeces of babies fed exclusively with breast milk | |
CN100421676C (en) | Lactic acid producing bacteria and lung function | |
Huang et al. | The in vivo assessment of safety and gastrointestinal survival of an orally administered novel probiotic, Propionibacterium jensenii 702, in a male Wistar rat model | |
EP3065825B1 (en) | Composition comprising lactobacillus plantarum | |
CN103987393A (en) | Composition comprising n-acetylcysteine and/or microencapsulated gastroprotected lysozyme in association with probiotic bacteria capable of restoring the stomach's own barrier effect which is lost during the pharmacological treatment of gastric hyperacidity | |
CN114381411B (en) | Lactococcus lactis JYLL-60 and application thereof in preparation of product for improving immunity | |
CN112725219B (en) | Bifidobacterium adolescentis strain and application thereof | |
Chaudhari et al. | In vitro and in vivo evaluation of probiotic potential and safety assessment of Bacillus coagulans SKB LAB-19 (MCC 0554) in humans and animal healthcare | |
Kumar et al. | Bifidobacteria for life betterment | |
CN113913334B (en) | Enterococcus faecalis EF-ZA1107-06 and application thereof | |
EP3031931B1 (en) | Lactobacillus rhamnosus food grade bacteria | |
US20230022942A1 (en) | Method for analyzing ileostomy subjects using a probiotic containing bacillus subtilis | |
KR20240040823A (en) | Vitamin B12 producing Limosilactobacillus fermentum PL9261 and the compositions for prevention or improvement of vitamin B12 deficiency containing Limosilactobacillus fermentum PL9261 as active gradient | |
Wang | Comparison of Microbial Quality of Commercial Probiotic Dietary Supplements | |
Mathipa | Pre-adaptation of selected probiotic strains to multiple stress factors: consequent effect on their stability and probiotic properties | |
Pachenari | An investigation of the potential of selected strains of Bifidobacterium to colonise the gastrointestinal tract of mice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |